US20060063743A1 - Peptide deformylase activated prodrugs - Google Patents
Peptide deformylase activated prodrugs Download PDFInfo
- Publication number
- US20060063743A1 US20060063743A1 US11/256,061 US25606105A US2006063743A1 US 20060063743 A1 US20060063743 A1 US 20060063743A1 US 25606105 A US25606105 A US 25606105A US 2006063743 A1 US2006063743 A1 US 2006063743A1
- Authority
- US
- United States
- Prior art keywords
- group
- compound
- chloro
- dichlorophenoxy
- phenol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108010026809 Peptide deformylase Proteins 0.000 title claims abstract description 9
- 239000000651 prodrug Substances 0.000 title description 37
- 229940002612 prodrug Drugs 0.000 title description 37
- 150000001875 compounds Chemical class 0.000 claims abstract description 98
- 238000000034 method Methods 0.000 claims abstract description 50
- 244000005700 microbiome Species 0.000 claims abstract description 32
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 30
- -1 ducarmycin Chemical compound 0.000 claims description 30
- 229910052760 oxygen Inorganic materials 0.000 claims description 30
- 239000001301 oxygen Substances 0.000 claims description 30
- 208000015181 infectious disease Diseases 0.000 claims description 24
- 239000001257 hydrogen Substances 0.000 claims description 23
- 229910052739 hydrogen Inorganic materials 0.000 claims description 23
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 22
- 229910052717 sulfur Inorganic materials 0.000 claims description 21
- 239000011593 sulfur Chemical group 0.000 claims description 20
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 19
- 239000003053 toxin Substances 0.000 claims description 17
- 229920006395 saturated elastomer Polymers 0.000 claims description 16
- 239000003937 drug carrier Substances 0.000 claims description 14
- 241001465754 Metazoa Species 0.000 claims description 13
- 229910052757 nitrogen Inorganic materials 0.000 claims description 13
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 12
- 208000031729 Bacteremia Diseases 0.000 claims description 12
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 12
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 claims description 12
- 125000003118 aryl group Chemical group 0.000 claims description 12
- NGNQZCDZXSOVQU-UHFFFAOYSA-N 8,16,18,26,34,36-hexahydroxyhentetracontane-2,6,10,14,24,28,32-heptone Chemical compound CCCCCC(O)CC(O)CC(=O)CCCC(=O)CC(O)CC(=O)CCCCCC(O)CC(O)CC(=O)CCCC(=O)CC(O)CC(=O)CCCC(C)=O NGNQZCDZXSOVQU-UHFFFAOYSA-N 0.000 claims description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- 231100000433 cytotoxic Toxicity 0.000 claims description 10
- 230000001472 cytotoxic effect Effects 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 208000024891 symptom Diseases 0.000 claims description 10
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 claims description 8
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 claims description 8
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 8
- 229930192392 Mitomycin Natural products 0.000 claims description 8
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims description 8
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 claims description 8
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 8
- 229940126575 aminoglycoside Drugs 0.000 claims description 8
- 229960003677 chloroquine Drugs 0.000 claims description 8
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 claims description 8
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 claims description 8
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 8
- 229960005420 etoposide Drugs 0.000 claims description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims description 8
- 229960001924 melphalan Drugs 0.000 claims description 8
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims description 8
- 229960004857 mitomycin Drugs 0.000 claims description 8
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 claims description 8
- 229940124530 sulfonamide Drugs 0.000 claims description 8
- ICUTUKXCWQYESQ-UHFFFAOYSA-N triclocarban Chemical compound C1=CC(Cl)=CC=C1NC(=O)NC1=CC=C(Cl)C(Cl)=C1 ICUTUKXCWQYESQ-UHFFFAOYSA-N 0.000 claims description 8
- 229960001325 triclocarban Drugs 0.000 claims description 8
- 229960003500 triclosan Drugs 0.000 claims description 8
- 241000251468 Actinopterygii Species 0.000 claims description 7
- 241000588724 Escherichia coli Species 0.000 claims description 7
- JBEHUBNEABQXHR-UHFFFAOYSA-N 2-cyclopropyl-1h-benzo[g]indole Chemical class C1CC1C1=CC2=CC=C(C=CC=C3)C3=C2N1 JBEHUBNEABQXHR-UHFFFAOYSA-N 0.000 claims description 6
- INCAQIRDTKGRNM-UHFFFAOYSA-N 2-cyclopropyl-1h-indole Chemical compound C1CC1C1=CC2=CC=CC=C2N1 INCAQIRDTKGRNM-UHFFFAOYSA-N 0.000 claims description 6
- 206010035664 Pneumonia Diseases 0.000 claims description 6
- 239000003242 anti bacterial agent Substances 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 6
- 125000004417 unsaturated alkyl group Chemical group 0.000 claims description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- KQODQNJLJQHFQV-UHFFFAOYSA-N (-)-hemiasterlin Natural products C1=CC=C2C(C(C)(C)C(C(=O)NC(C(=O)N(C)C(C=C(C)C(O)=O)C(C)C)C(C)(C)C)NC)=CN(C)C2=C1 KQODQNJLJQHFQV-UHFFFAOYSA-N 0.000 claims description 4
- HJIAMFHSAAEUKR-UHFFFAOYSA-N (2-hydroxyphenyl)-phenylmethanone Chemical class OC1=CC=CC=C1C(=O)C1=CC=CC=C1 HJIAMFHSAAEUKR-UHFFFAOYSA-N 0.000 claims description 4
- MCEHFIXEKNKSRW-LBPRGKRZSA-N (2s)-2-[[3,5-dichloro-4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]pentanedioic acid Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=C(Cl)C=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1Cl MCEHFIXEKNKSRW-LBPRGKRZSA-N 0.000 claims description 4
- XLVOWGDFXAVSFE-UHFFFAOYSA-N (4-amino-2-methylsulfanylpyrimidin-5-yl)methanol Chemical compound CSC1=NC=C(CO)C(N)=N1 XLVOWGDFXAVSFE-UHFFFAOYSA-N 0.000 claims description 4
- KQODQNJLJQHFQV-MKWZWQCGSA-N (e,4s)-4-[[(2s)-3,3-dimethyl-2-[[(2s)-3-methyl-2-(methylamino)-3-(1-methylindol-3-yl)butanoyl]amino]butanoyl]-methylamino]-2,5-dimethylhex-2-enoic acid Chemical compound C1=CC=C2C(C(C)(C)[C@@H](C(=O)N[C@H](C(=O)N(C)[C@H](\C=C(/C)C(O)=O)C(C)C)C(C)(C)C)NC)=CN(C)C2=C1 KQODQNJLJQHFQV-MKWZWQCGSA-N 0.000 claims description 4
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 claims description 4
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical class O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 claims description 4
- CYTRYZRMQHRCCC-UHFFFAOYSA-N 2-chloro-6-(2,4-dichlorophenoxy)phenol Chemical compound OC1=C(Cl)C=CC=C1OC1=CC=C(Cl)C=C1Cl CYTRYZRMQHRCCC-UHFFFAOYSA-N 0.000 claims description 4
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 claims description 4
- XUIBGCBAMNTLFK-UHFFFAOYSA-N 3-chloro-2-(2,4-dichlorophenoxy)phenol Chemical compound OC1=CC=CC(Cl)=C1OC1=CC=C(Cl)C=C1Cl XUIBGCBAMNTLFK-UHFFFAOYSA-N 0.000 claims description 4
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 claims description 4
- SOLHLLBMOQIIJA-UHFFFAOYSA-N 4-chloro-2-(2,4-dichlorophenoxy)phenol Chemical compound OC1=CC=C(Cl)C=C1OC1=CC=C(Cl)C=C1Cl SOLHLLBMOQIIJA-UHFFFAOYSA-N 0.000 claims description 4
- RANONBLIHMVXAJ-UHFFFAOYSA-N 4-hydroxycyclophosphamide Chemical compound OC1CCOP(=O)(N(CCCl)CCCl)N1 RANONBLIHMVXAJ-UHFFFAOYSA-N 0.000 claims description 4
- KJRCCPXLMQDVHA-UHFFFAOYSA-N 4-pyridin-2-yl-3h-1,3-oxazol-2-one Chemical compound O1C(=O)NC(C=2N=CC=CC=2)=C1 KJRCCPXLMQDVHA-UHFFFAOYSA-N 0.000 claims description 4
- LGZKGOGODCLQHG-CYBMUJFWSA-N 5-[(2r)-2-hydroxy-2-(3,4,5-trimethoxyphenyl)ethyl]-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC=C1C[C@@H](O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-CYBMUJFWSA-N 0.000 claims description 4
- RKWKLXWJFVLONV-UHFFFAOYSA-N 5-chloro-2-(2,5-dichlorophenoxy)phenol Chemical compound OC1=CC(Cl)=CC=C1OC1=CC(Cl)=CC=C1Cl RKWKLXWJFVLONV-UHFFFAOYSA-N 0.000 claims description 4
- IMNGAWPVLXMWNF-UHFFFAOYSA-N 5-chloro-2-(3,4-dichlorophenoxy)phenol Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C(Cl)=C1 IMNGAWPVLXMWNF-UHFFFAOYSA-N 0.000 claims description 4
- NBTZARQCAXXFSE-UHFFFAOYSA-N 5-chloro-2-(3,5-dichlorophenoxy)phenol Chemical compound OC1=CC(Cl)=CC=C1OC1=CC(Cl)=CC(Cl)=C1 NBTZARQCAXXFSE-UHFFFAOYSA-N 0.000 claims description 4
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 4
- 108010006654 Bleomycin Proteins 0.000 claims description 4
- 229960005532 CC-1065 Drugs 0.000 claims description 4
- 229930186147 Cephalosporin Natural products 0.000 claims description 4
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 claims description 4
- 235000001258 Cinchona calisaya Nutrition 0.000 claims description 4
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 4
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 claims description 4
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 claims description 4
- 108010015899 Glycopeptides Proteins 0.000 claims description 4
- 102000002068 Glycopeptides Human genes 0.000 claims description 4
- 229930195695 Halichondrin Natural products 0.000 claims description 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 4
- JXLYSJRDGCGARV-PJXZDTQASA-N Leurosidine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-PJXZDTQASA-N 0.000 claims description 4
- LPGWZGMPDKDHEP-HLTPFJCJSA-N Leurosine Chemical compound C([C@]1([C@@H]2O1)CC)N(CCC=1C3=CC=CC=C3NC=11)C[C@H]2C[C@]1(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC LPGWZGMPDKDHEP-HLTPFJCJSA-N 0.000 claims description 4
- LPGWZGMPDKDHEP-GKWAKPNHSA-N Leurosine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@]6(CC)O[C@@H]6[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C LPGWZGMPDKDHEP-GKWAKPNHSA-N 0.000 claims description 4
- HRHKSTOGXBBQCB-UHFFFAOYSA-N Mitomycin E Natural products O=C1C(N)=C(C)C(=O)C2=C1C(COC(N)=O)C1(OC)C3N(C)C3CN12 HRHKSTOGXBBQCB-UHFFFAOYSA-N 0.000 claims description 4
- 241000588655 Moraxella catarrhalis Species 0.000 claims description 4
- 229930182555 Penicillin Natural products 0.000 claims description 4
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims description 4
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims description 4
- 241000191963 Staphylococcus epidermidis Species 0.000 claims description 4
- HATRDXDCPOXQJX-UHFFFAOYSA-N Thapsigargin Natural products CCCCCCCC(=O)OC1C(OC(O)C(=C/C)C)C(=C2C3OC(=O)C(C)(O)C3(O)C(CC(C)(OC(=O)C)C12)OC(=O)CCC)C HATRDXDCPOXQJX-UHFFFAOYSA-N 0.000 claims description 4
- 229940122803 Vinca alkaloid Drugs 0.000 claims description 4
- JXLYSJRDGCGARV-KSNABSRWSA-N ac1l29ym Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-KSNABSRWSA-N 0.000 claims description 4
- 229960003896 aminopterin Drugs 0.000 claims description 4
- TXFLGZOGNOOEFZ-UHFFFAOYSA-N bis(2-chloroethyl)amine Chemical compound ClCCNCCCl TXFLGZOGNOOEFZ-UHFFFAOYSA-N 0.000 claims description 4
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical class N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 4
- 229930188550 carminomycin Natural products 0.000 claims description 4
- XREUEWVEMYWFFA-CSKJXFQVSA-N carminomycin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XREUEWVEMYWFFA-CSKJXFQVSA-N 0.000 claims description 4
- XREUEWVEMYWFFA-UHFFFAOYSA-N carminomycin I Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XREUEWVEMYWFFA-UHFFFAOYSA-N 0.000 claims description 4
- 229950001725 carubicin Drugs 0.000 claims description 4
- 229940124587 cephalosporin Drugs 0.000 claims description 4
- 150000001780 cephalosporins Chemical class 0.000 claims description 4
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims description 4
- 229960005091 chloramphenicol Drugs 0.000 claims description 4
- 229960003260 chlorhexidine Drugs 0.000 claims description 4
- 229960003405 ciprofloxacin Drugs 0.000 claims description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 4
- 229960004316 cisplatin Drugs 0.000 claims description 4
- 229960001338 colchicine Drugs 0.000 claims description 4
- LGZKGOGODCLQHG-UHFFFAOYSA-N combretastatin Natural products C1=C(O)C(OC)=CC=C1CC(O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-UHFFFAOYSA-N 0.000 claims description 4
- 229960003077 cycloserine Drugs 0.000 claims description 4
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 4
- 229960000975 daunorubicin Drugs 0.000 claims description 4
- IMHDGJOMLMDPJN-UHFFFAOYSA-N dihydroxybiphenyl Natural products OC1=CC=CC=C1C1=CC=CC=C1O IMHDGJOMLMDPJN-UHFFFAOYSA-N 0.000 claims description 4
- 229960004679 doxorubicin Drugs 0.000 claims description 4
- 206010014665 endocarditis Diseases 0.000 claims description 4
- 229930013356 epothilone Natural products 0.000 claims description 4
- 150000003883 epothilone derivatives Chemical class 0.000 claims description 4
- SIHZWGODIRRSRA-ONEGZZNKSA-N erbstatin Chemical compound OC1=CC=C(O)C(\C=C\NC=O)=C1 SIHZWGODIRRSRA-ONEGZZNKSA-N 0.000 claims description 4
- LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 claims description 4
- 229960000752 etoposide phosphate Drugs 0.000 claims description 4
- ANUSOIHIIPAHJV-UHFFFAOYSA-N fenticlor Chemical compound OC1=CC=C(Cl)C=C1SC1=CC(Cl)=CC=C1O ANUSOIHIIPAHJV-UHFFFAOYSA-N 0.000 claims description 4
- 229950005344 fenticlor Drugs 0.000 claims description 4
- 229940124307 fluoroquinolone Drugs 0.000 claims description 4
- 229940045109 genistein Drugs 0.000 claims description 4
- 235000006539 genistein Nutrition 0.000 claims description 4
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 claims description 4
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 claims description 4
- 108010057806 hemiasterlin Proteins 0.000 claims description 4
- 229930187626 hemiasterlin Natural products 0.000 claims description 4
- ACGUYXCXAPNIKK-UHFFFAOYSA-N hexachlorophene Chemical compound OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(O)C(Cl)=CC(Cl)=C1Cl ACGUYXCXAPNIKK-UHFFFAOYSA-N 0.000 claims description 4
- 229960004068 hexachlorophene Drugs 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims description 4
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 4
- 239000003120 macrolide antibiotic agent Substances 0.000 claims description 4
- 229940041033 macrolides Drugs 0.000 claims description 4
- 229960001428 mercaptopurine Drugs 0.000 claims description 4
- FBOZXECLQNJBKD-UHFFFAOYSA-N methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-UHFFFAOYSA-N 0.000 claims description 4
- 229960000485 methotrexate Drugs 0.000 claims description 4
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 4
- HRHKSTOGXBBQCB-VFWICMBZSA-N methylmitomycin Chemical compound O=C1C(N)=C(C)C(=O)C2=C1[C@@H](COC(N)=O)[C@@]1(OC)[C@H]3N(C)[C@H]3CN12 HRHKSTOGXBBQCB-VFWICMBZSA-N 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- 229960001180 norfloxacin Drugs 0.000 claims description 4
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 claims description 4
- 239000002777 nucleoside Substances 0.000 claims description 4
- 125000003835 nucleoside group Chemical group 0.000 claims description 4
- 150000002960 penicillins Chemical class 0.000 claims description 4
- 229910052698 phosphorus Inorganic materials 0.000 claims description 4
- 239000003910 polypeptide antibiotic agent Substances 0.000 claims description 4
- 229950004406 porfiromycin Drugs 0.000 claims description 4
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 claims description 4
- YBBJKCMMCRQZMA-UHFFFAOYSA-N pyrithione Chemical compound ON1C=CC=CC1=S YBBJKCMMCRQZMA-UHFFFAOYSA-N 0.000 claims description 4
- 229960001285 quercetin Drugs 0.000 claims description 4
- 235000005875 quercetin Nutrition 0.000 claims description 4
- 229960001404 quinidine Drugs 0.000 claims description 4
- 229960000948 quinine Drugs 0.000 claims description 4
- 150000007660 quinolones Chemical class 0.000 claims description 4
- UOWVMDUEMSNCAV-WYENRQIDSA-N rachelmycin Chemical compound C1([C@]23C[C@@H]2CN1C(=O)C=1NC=2C(OC)=C(O)C4=C(C=2C=1)CCN4C(=O)C1=CC=2C=4CCN(C=4C(O)=C(C=2N1)OC)C(N)=O)=CC(=O)C1=C3C(C)=CN1 UOWVMDUEMSNCAV-WYENRQIDSA-N 0.000 claims description 4
- 229960005404 sulfamethoxazole Drugs 0.000 claims description 4
- 150000003456 sulfonamides Chemical class 0.000 claims description 4
- 125000004434 sulfur atom Chemical group 0.000 claims description 4
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 claims description 4
- IXFPJGBNCFXKPI-FSIHEZPISA-N thapsigargin Chemical compound CCCC(=O)O[C@H]1C[C@](C)(OC(C)=O)[C@H]2[C@H](OC(=O)CCCCCCC)[C@@H](OC(=O)C(\C)=C/C)C(C)=C2[C@@H]2OC(=O)[C@@](C)(O)[C@]21O IXFPJGBNCFXKPI-FSIHEZPISA-N 0.000 claims description 4
- KVSKGMLNBAPGKH-UHFFFAOYSA-N tribromosalicylanilide Chemical compound OC1=C(Br)C=C(Br)C=C1C(=O)NC1=CC=C(Br)C=C1 KVSKGMLNBAPGKH-UHFFFAOYSA-N 0.000 claims description 4
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 claims description 4
- 229960001082 trimethoprim Drugs 0.000 claims description 4
- 229960001722 verapamil Drugs 0.000 claims description 4
- 229960003048 vinblastine Drugs 0.000 claims description 4
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 4
- 229960004528 vincristine Drugs 0.000 claims description 4
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 4
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 4
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 claims description 4
- 229960004355 vindesine Drugs 0.000 claims description 4
- 241000588697 Enterobacter cloacae Species 0.000 claims description 3
- 241000495778 Escherichia faecalis Species 0.000 claims description 3
- 241000606768 Haemophilus influenzae Species 0.000 claims description 3
- 241000588915 Klebsiella aerogenes Species 0.000 claims description 3
- 208000006816 Neonatal Sepsis Diseases 0.000 claims description 3
- 206010031252 Osteomyelitis Diseases 0.000 claims description 3
- 206010033078 Otitis media Diseases 0.000 claims description 3
- 230000003115 biocidal effect Effects 0.000 claims description 3
- 208000019206 urinary tract infection Diseases 0.000 claims description 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 2
- 208000014912 Central Nervous System Infections Diseases 0.000 claims description 2
- 206010048461 Genital infection Diseases 0.000 claims description 2
- 206010022678 Intestinal infections Diseases 0.000 claims description 2
- 206010024971 Lower respiratory tract infections Diseases 0.000 claims description 2
- 206010071301 Perihepatitis Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 208000012876 acute enteritis Diseases 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 208000025222 central nervous system infectious disease Diseases 0.000 claims description 2
- 206010009887 colitis Diseases 0.000 claims description 2
- 208000001606 epiglottitis Diseases 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000004437 phosphorous atom Chemical group 0.000 claims description 2
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 claims description 2
- 201000009890 sinusitis Diseases 0.000 claims description 2
- 201000009906 Meningitis Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 65
- 239000003795 chemical substances by application Substances 0.000 description 36
- 108090000790 Enzymes Proteins 0.000 description 28
- 102000004190 Enzymes Human genes 0.000 description 28
- 238000009472 formulation Methods 0.000 description 28
- 239000004480 active ingredient Substances 0.000 description 17
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- 239000000758 substrate Substances 0.000 description 15
- 241000196324 Embryophyta Species 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 239000003921 oil Substances 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 238000002560 therapeutic procedure Methods 0.000 description 11
- 125000000217 alkyl group Chemical group 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 125000003342 alkenyl group Chemical group 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 239000008187 granular material Substances 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 7
- 230000000813 microbial effect Effects 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 125000001424 substituent group Chemical group 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 231100000765 toxin Toxicity 0.000 description 7
- 108700012359 toxins Proteins 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 125000000304 alkynyl group Chemical group 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 239000003995 emulsifying agent Substances 0.000 description 5
- 239000003925 fat Substances 0.000 description 5
- 235000019197 fats Nutrition 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 239000003381 stabilizer Substances 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- 238000004679 31P NMR spectroscopy Methods 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical group C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 0 [4*]C([H])(NC([H])=O)C(=C)CC([5*])([6*])P(=C)(CCCC)CCCC Chemical compound [4*]C([H])(NC([H])=O)C(=C)CC([5*])([6*])P(=C)(CCCC)CCCC 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- 125000001931 aliphatic group Chemical group 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 125000005647 linker group Chemical group 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000003039 volatile agent Substances 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 206010061217 Infestation Diseases 0.000 description 3
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 239000012300 argon atmosphere Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 150000005829 chemical entities Chemical class 0.000 description 3
- 239000000306 component Substances 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 230000006198 deformylation Effects 0.000 description 3
- 238000006344 deformylation reaction Methods 0.000 description 3
- 239000002274 desiccant Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 125000001188 haloalkyl group Chemical group 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- PYUSHNKNPOHWEZ-YFKPBYRVSA-N N-formyl-L-methionine Chemical group CSCC[C@@H](C(O)=O)NC=O PYUSHNKNPOHWEZ-YFKPBYRVSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- DFOSQNBSOFVHDS-POMGOJLNSA-N [H]C(=O)N[C@@]([H])(CCSC)C(=O)NC(CC)P(=O)(OC1=CC=CC=C1)OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1 Chemical compound [H]C(=O)N[C@@]([H])(CCSC)C(=O)NC(CC)P(=O)(OC1=CC=CC=C1)OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1 DFOSQNBSOFVHDS-POMGOJLNSA-N 0.000 description 2
- MIYHJJZHMLULKJ-WCCKRBBISA-N [S].CSCC[C@H](N)C(O)=O Chemical compound [S].CSCC[C@H](N)C(O)=O MIYHJJZHMLULKJ-WCCKRBBISA-N 0.000 description 2
- 125000002015 acyclic group Chemical group 0.000 description 2
- 125000002723 alicyclic group Chemical group 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 230000009969 flowable effect Effects 0.000 description 2
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical class C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 150000004679 hydroxides Chemical class 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000000816 peptidomimetic Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 125000002924 primary amino group Chemical class [H]N([H])* 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- HVLLSGMXQDNUAL-UHFFFAOYSA-N triphenyl phosphite Chemical compound C=1C=CC=CC=1OP(OC=1C=CC=CC=1)OC1=CC=CC=C1 HVLLSGMXQDNUAL-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 238000005292 vacuum distillation Methods 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
- IVJFXSLMUSQZMC-UHFFFAOYSA-N 1,3-dithiole Chemical class C1SC=CS1 IVJFXSLMUSQZMC-UHFFFAOYSA-N 0.000 description 1
- OSUKSSHOHKZSJC-UHFFFAOYSA-N 12591-02-5 Chemical compound ClP(=O)=O OSUKSSHOHKZSJC-UHFFFAOYSA-N 0.000 description 1
- LGEZTMRIZWCDLW-UHFFFAOYSA-N 14-methylpentadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C LGEZTMRIZWCDLW-UHFFFAOYSA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- SFAAOBGYWOUHLU-UHFFFAOYSA-N 2-ethylhexyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(CC)CCCC SFAAOBGYWOUHLU-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- TYMLOMAKGOJONV-UHFFFAOYSA-N 4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000589291 Acinetobacter Species 0.000 description 1
- 102000004400 Aminopeptidases Human genes 0.000 description 1
- 108090000915 Aminopeptidases Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 239000004358 Butane-1, 3-diol Substances 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- RJZBDTRVVCVLNN-UHFFFAOYSA-N C=C(=C)(CCCC)OC1=CC=C(COC)C=C1 Chemical compound C=C(=C)(CCCC)OC1=CC=C(COC)C=C1 RJZBDTRVVCVLNN-UHFFFAOYSA-N 0.000 description 1
- ALASJIRHDYLHDA-UHFFFAOYSA-N CCC(NC(=O)OCC1=CC=CC=C1)P(=O)(O)OC1=CC=CC=C1 Chemical compound CCC(NC(=O)OCC1=CC=CC=C1)P(=O)(O)OC1=CC=CC=C1 ALASJIRHDYLHDA-UHFFFAOYSA-N 0.000 description 1
- PMFWXYLLGBWFAN-UHFFFAOYSA-N CCC(NC(=O)OCC1=CC=CC=C1)P(=O)(OC1=CC=CC=C1)OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl Chemical compound CCC(NC(=O)OCC1=CC=CC=C1)P(=O)(OC1=CC=CC=C1)OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl PMFWXYLLGBWFAN-UHFFFAOYSA-N 0.000 description 1
- VMMMBCJXTBUYKN-UHFFFAOYSA-N CCC(NC(=O)OCC1=CC=CC=C1)P(=O)(OC1=CC=CC=C1)OC1=CC=CC=C1 Chemical compound CCC(NC(=O)OCC1=CC=CC=C1)P(=O)(OC1=CC=CC=C1)OC1=CC=CC=C1 VMMMBCJXTBUYKN-UHFFFAOYSA-N 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000036209 Intraabdominal Infections Diseases 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027241 Meningitis haemophilus Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 206010058674 Pelvic Infection Diseases 0.000 description 1
- 206010035728 Pneumonia pneumococcal Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- DFOSQNBSOFVHDS-UHFFFAOYSA-N [H]C(=O)N([H])C(CCSC)C(=O)NC(CC)P(=O)(OC1=CC=CC=C1)OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl Chemical compound [H]C(=O)N([H])C(CCSC)C(=O)NC(CC)P(=O)(OC1=CC=CC=C1)OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl DFOSQNBSOFVHDS-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- XJLATMLVMSFZBN-VYDXJSESSA-N actinonin Chemical compound CCCCC[C@H](CC(=O)NO)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1CO XJLATMLVMSFZBN-VYDXJSESSA-N 0.000 description 1
- XJLATMLVMSFZBN-UHFFFAOYSA-N actinonine Natural products CCCCCC(CC(=O)NO)C(=O)NC(C(C)C)C(=O)N1CCCC1CO XJLATMLVMSFZBN-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 150000001356 alkyl thiols Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 229940124339 anthelmintic agent Drugs 0.000 description 1
- 239000000921 anthelmintic agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000842 anti-protozoal effect Effects 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003904 antiprotozoal agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 229910052789 astatine Inorganic materials 0.000 description 1
- RYXHOMYVWAEKHL-UHFFFAOYSA-N astatine atom Chemical compound [At] RYXHOMYVWAEKHL-UHFFFAOYSA-N 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 150000008107 benzenesulfonic acids Chemical class 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- PUJDIJCNWFYVJX-UHFFFAOYSA-N benzyl carbamate Chemical compound NC(=O)OCC1=CC=CC=C1 PUJDIJCNWFYVJX-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- KWEDUNSJJZVRKR-UHFFFAOYSA-N carbononitridic azide Chemical group [N-]=[N+]=NC#N KWEDUNSJJZVRKR-UHFFFAOYSA-N 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 1
- 101150060629 def gene Proteins 0.000 description 1
- 231100000223 dermal penetration Toxicity 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 150000004662 dithiols Chemical class 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000002359 drug metabolite Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000004495 emulsifiable concentrate Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000003248 enzyme activator Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 125000004970 halomethyl group Chemical group 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002664 inhalation therapy Methods 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 235000013847 iso-butane Nutrition 0.000 description 1
- 229940078545 isocetyl stearate Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- LGRLWUINFJPLSH-UHFFFAOYSA-N methanide Chemical compound [CH3-] LGRLWUINFJPLSH-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000006225 natural substrate Substances 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000008251 pharmaceutical emulsion Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-M pivalate Chemical compound CC(C)(C)C([O-])=O IUGYQRQAERSCNH-UHFFFAOYSA-M 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229940124606 potential therapeutic agent Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000022218 streptococcal pneumonia Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 150000003462 sulfoxides Chemical group 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 150000003573 thiols Chemical group 0.000 description 1
- VRORTNGXAKZJML-UHFFFAOYSA-N thyropropic acid Chemical compound IC1=CC(CCC(=O)O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 VRORTNGXAKZJML-UHFFFAOYSA-N 0.000 description 1
- 229950000464 thyropropic acid Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- ZBZJXHCVGLJWFG-UHFFFAOYSA-N trichloromethyl(.) Chemical compound Cl[C](Cl)Cl ZBZJXHCVGLJWFG-UHFFFAOYSA-N 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
- C07F9/40—Esters thereof
- C07F9/4071—Esters thereof the ester moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4084—Esters with hydroxyaryl compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
Definitions
- the present invention relates to the field of Enzyme Catalyzed Therapeutic Activation (ECTATM) therapy and in particular, ECTA therapies specific for microorganisms that express Peptide Deformylase (“PDF”).
- ECTATM Enzyme Catalyzed Therapeutic Activation
- PDF Peptide Deformylase
- Enzyme Catalyzed Therapeutic Activation (ECTATM) therapy is a novel technology that provides unique prodrug substrates for target enzymes. Unlike conventional therapies, ECTA prodrugs neither inhibit nor irreversibly inactivate the target enzyme.
- Target enzymes convert the ECTA prodrug into a toxin preferentially within the target cell or in an environment wherein the target enzyme is expressed as compared to an environment where it is absent, as in an infected cell. Because the compounds do not require a targeting agent, they can be directly utilized, topically or systemically.
- ECTA molecules do not, in most instances, yield cytotoxic products spontaneously (without target enzyme activation). They are not be appreciably activated by non-targeted enzymes, as this may result in toxicity to non-diseased or non-infected tissue. Table 1 summarizes the characteristics of ECTA molecules and enzyme activators. TABLE 1 Characteristics of ECTA Target Enzymes Characteristics of ECTA Prodrugs Infectious Disease: Must be present Must be able to get into cells (by only in target cells (including itself or as prodrug). diseased cells, bacteria, fungi, etc.). The enzyme should be necessary for continued viability or pathogenicity.
- metabolic pathways being present in the pathogenic organisms, but absent in the host are a source of potential ECTA target enzymes.
- some pathways, as well as the enzymes involved have only been found in bacteria, fungi and plants and not in mammalian cells.
- One example is the synthesis of “essential” amino acids—amino acids that animals cannot synthesize and must ingest with food. Nelson and Cox (1972).
- PDF Peptide Deformylase
- EC 3.5.1.88 Peptide Deformylase
- the enzyme is present and active in bacteria (Meinnel et al, 1993), but has not been reported to be active in mammalian cells. Sequences homologous to bacterial PDF sequences have been recently found in mammals but their exact function is unknown. Giglione (2000a) and (2000b).
- Dithiols can act as non-specific PDF inhibitors by coordination of sulfhydryl groups with the active site metal ion. Rajagopalan (1997). In case of 1,2- or 1,3-dithiols a slow extraction of the metal ion from the active site takes place. The formation of stable 5- or 6-membered rings, respectively, each containing two metal-sulfur bonds, accounts for this effect.
- a rationally designed combinatorial library was used to select mechanism-based PDF inhibitors of the general structure HS—CH 2 —CH(R a )—CONH—CH(R b )—CONH—R c .
- the optimal inhibitor selected from the library possesses an n-Bu group as an R a , R b ⁇ —(CH 2 ) 3 —NH—C( ⁇ NH)—NH 2 , and R c is 2-naphthalene.
- This compound acts as a competitive PDF inhibitor with a K i of 15 nM.
- Jayasekera et al. (2000) describes a series of non-peptidic compounds structurally related to the known anticholesteremic thyropropic acid to inhibit E. coli PDF. Actinonin is reported to be a potent PDF inhibitor with activity in the subnanomolar K i range. Chen (2000) and Guilloteau et al (2002).
- the present invention relates to a compound having the structure: wherein:
- R 1 is hydrogen or CH 3 ;
- R 4 is selected from the group consisting of a substituted or unsubstituted aryl group, a substituted or unsubstituted, saturated or unsaturated C 1 -C 6 alkyl group and CH 2 CH 2 XCH 3 , wherein X is selected from the group consisting of oxygen, sulfur and CH 2 ;
- R 5 and R 6 are independently selected from the group consisting of hydrogen, a substituted or unsubstituted C 5 -C 14 aryl group and a substituted or unsubstituted, saturated or unsaturated C 1 -C 6 alkyl group;
- a 1 is either absent, in which case the carbon to which it was attached becomes a CH 2 group, or A 1 is selected from the group consisting of oxygen, sulfur, NH, NOH, NR 8 , and CR 9 R 10 , wherein R 8 , R 9 and R 10 are independently selected from the group consisting of hydrogen and C 1 -C 6 alkyl;
- a 2 is either absent, in which case the carbon to which it was attached becomes a CH 2 group, or A 2 is selected from the group consisting of oxygen, sulfur, NH, NOH and NR 11 wherein R 11 is selected from the group consisting of hydrogen and C 1 -C 6 alkyl;
- B 1 is either absent or is selected from the group consisting of oxygen, sulfur, NR 12 and CR 13 R 14 , wherein R 12 R 13 and R 14 are independently selected from the group consisting of hydrogen and a substituted or unsubstituted saturated or unsaturated alkyl;
- B 2 is selected from the group consisting of carbon, oxygen and nitrogen, wherein, when B 2 is oxygen, R 5 and R 6 are absent and when B 2 is nitrogen, one of R 5 or R 6 is absent;
- B 1 may be joined through R 12 , R 13 or R 14 to R 5 or R 6 to form a saturated or unsaturated, substituted or unsubstituted ring which may contain 0-3 nitrogen atoms and/or 0-1 oxygen or sulfur atoms;
- B 3 and B 4 are independently the same or different and are absent or are selected from the group consisting of oxygen, sulfur, NH, CH 2 , NR 17 , CHR 18 , CR 21 R 22 and, when either linker 1 -B 5 -Toxin 1 or linker 2 -B 6 -Toxin 2 is absent, OR 15 , SR 16 , NR 19 R 20 and CR 23 R 24 R 25 , wherein R 15 —R 25 are independently selected from the group consisting of hydrogen, substituted or unsubstituted, saturated or unsaturated alkyl and substituted or unsubstituted aryl;
- B 3 or B 4 may be joined through one of R 15 —R 25 to B 1 , R 5 or R 6 to form a saturated or unsaturated, substituted or unsubstituted ring which contains one phosphorus atom and which may contain 0-3 nitrogen atoms and/or 0-1 oxygen or sulfur atoms;
- B 5 and B 6 are independently the same or different and are absent or are selected from the group consisting of oxygen, sulfur, OC( ⁇ O), SC( ⁇ S), OC( ⁇ O)NH, SC( ⁇ S)NH, OC( ⁇ S)NH, N(R 26 ) and C(R 27 )(R 28 ), wherein R 26 , R 27 and R 28 are independently selected from the group consisting of hydrogen and a substituted or unsubstituted, saturated or unsaturated alkyl;
- Linker 1 and Linker 2 are independently the same or different and are absent or present and, if present, are traceless; and,
- One of Toxin 1 or Toxin 2 may be absent.
- R 1 is hydrogen and R 4 is CH 2 CH 2 XCH 3 , and X is selected from the group consisting of CH 2 , sulfur and oxygen.
- X is sulfur
- a 1 and A 2 are both oxygen.
- Linker 1 -B 5 -Toxin 1 is absent.
- B 1 is absent.
- B 2 is carbon
- B 2 is nitrogen
- B 3 is selected from the group consisting of OH, OCH 3 , OCH 2 CH 3 and OC 6 H 5 .
- Linker 2 is selected from the group consisting of
- B 6 is absent.
- Toxin 1 and Toxin 2 are independently selected from the group consisting of aminoglycosides, mitomycin, CC-1065, ducarmycin, cyclopropyl indole, cyclopropyl benzoindole analogs, anthracyclins, vinca alkaloids, mitomycins, bleomycins, penicillins, cephalosporins, oxacillins, carbopenems, tetracyclins, chloramphenicols, macrolides, cycliserines, fluoroquinolones (including, but not limited to, ciprofloxacin and norfloxacin), glycopeptides, aminoglycosides, peptide antibiotics, oxazolidinones, quinolones, sulfonamides, cytotoxic nucleosides, pteridine family, nitrogen mustards, polyhalogenated biaryl ethers, diynen
- etoposide phosphate melphalan, vindesine, vinblastine, vincristine, leurosidine, leurosine, bis-(2-chloroethyl)amine, trichlorcarban, trichlorocarbanilide, triclosan, tribromosalicylanilide, sulphamethoxazole, chloramphenicol, cycloserine, trimethoprim, chlorhexidine, hexachlorophene, fentichlor, 5-chloro-2-(2,4-dichlorophenoxy)phenol, 4-chloro-2-(2,4-dichlorophenoxy)phenol, 3-chloro-2-(2,4-dichlorophenoxy)phenol, 6-chloro-2-(2,4-dichlorophenoxy)phenol, 5-chloro-2-(3,4-dichlorophenoxy)phenol, 5-chloro-2-(2,5-dichlorophenoxy)phenol, 5-chloro-2-(3,5
- Toxin 2 is a quinolone.
- Toxin 2 is selected from the group consisting of triclosan, cyclopropylindole, cyclopropylbenzoindole and derivatives thereof.
- B 1 is joined to R 5 or R 6 to form a ring.
- An aspect of this invention is a compound having the structure:
- An aspect of this invention is a composition comprising a compound hereof and a pharmaceutically acceptable carrier.
- An aspect of this invention is a method for the treatment of a disease caused by a microorganism expressing a peptide deformylase enzyme, comprising administering an effective amount of a compound of claim 1 to a subject in need thereof.
- Also provided by this invention is a method for inhibiting the growth of a microorganism that expresses PDF by contacting the microorganism with an effective amount of the compound as describe above.
- This method inhibits the growth of a gram-positive or gram-negative microorganism, e.g., of S. aureus, S. epidermidis, K. pneumoniae, E. aerogenes, E. cloacae, M. catarrhalis, E. coli, E. faecalis, H. influenzae or P. aeruginosa.
- This method can be practiced in vitro, ex vivo and in vivo.
- a method for alleviating the symptoms of an infection by a PDF expressing microorganism in a subject by administering or delivering to the subject an effective amount of the compound described above.
- a “subject” is defined herein and includes mammals such as human patients.
- This invention also provides a composition comprising the prodrug compounds as described above, alone or in combination with other compounds or other agents, known or yet to be discovered, and a carrier.
- the carrier is another molecule or an inert substance such as a plate or column.
- the carrier is a pharmaceutically acceptable carrier.
- Pharmaceutically acceptable carriers are known in the art and described briefly above.
- Table 1 shows a list of non-limiting charactertistics of ECTA target enzymes and ECTA prodrugs.
- Table 2 is a non-limiting list of bacteria that express PDF and therefore are expected to be susceptible to the compounds of this invention.
- FIG. 1 is a proposed reaction scheme for PDF activation of the compounds of this invention.
- a cell includes a plurality of cells, including mixtures thereof.
- compositions and methods include the recited elements, but do not exclude others.
- Consisting essentially of when used to define compositions and methods, shall mean excluding other elements of any essential significance to the combination. Thus, a composition consisting essentially of the elements as defined herein would not exclude trace contaminants from the isolation and purification method and pharmaceutically acceptable carriers, such as phosphate buffered saline, preservatives, and the like.
- Consisting of shall mean excluding more than trace elements of other ingredients and substantial method steps for administering the compositions of this invention. Embodiments defined by each of these transition terms are within the scope of this invention.
- peptidomimetic refers to a compound containing non-peptidic structural elements that is capable of mimicking or antagonizing the biological action(s) of a natural parent peptide.
- substituted includes, but is not limited to halogen atoms and halomethyl groups such as CF 3 and CCl 3 ; oxygen containing groups such as oxo, hydroxy, carboxy, carboxyalkyl, alkoxy, alkoyl, alkoyloxy, aryloxy, aryloyl, and aryloyloxy; nitrogen containing groups such as amino, alkylamino, dialkylamino, cyano, azide and nitro; sulfur containing groups such as thiol, alkylthiol, sulfonyl and sulfoxide; heterocyclic groups which may themselves be substituted; alkyl groups which may themselves be substituted; and aryl groups which may themselves be substituted.
- oxygen containing groups such as oxo, hydroxy, carboxy, carboxyalkyl, alkoxy, alkoyl, alkoyloxy, aryloxy, aryloyl, and aryloyloxy
- alkyl refers to any branched or unbranched, cyclic or acyclic, saturated (alkyl) or unsaturated (alkenyl or alkynyl) hydrocarbyl radical. This term is not limited to a monovalent radical. Where cyclic, the alkyl group is C 3 to C 12 . Where acyclic, the alkyl group is C 1 to C 16 .
- alkoxy and aryloxy means alkyl-O and aryl-O groups, respectively. Reference to “alkoyl” and “aryloyl” groups means alkyl-CO and aryl-CO, respectively.
- aryl refers to an aromatic group, such as phenyl or napthyl, or a heteroatomic group containing one or more heteroatom, such as pyridyl, pyrrolyl, furanyl and thiophenyl. This term is not limited to a monovalent radical.
- aromatic refers to any compound characterized by the presence of at least one benzene ring. Examples of aromatic groups include, but are not limited to, benzene and naphthalene.
- alkyl and aryl groups may be substituted or unsubstituted.
- aliphatic refers to any and all organic compounds of hydrogen and carbon characterized by a straight chain of the carbon atoms.
- the subgroups of “aliphatic” compounds includes alkanes, alkenes, and alkynes.
- the aliphatic groups may be unsubstituted or substituted. See above for examples of substituents.
- alicyclic refers to and covers any and all organic compounds of hydrogen and carbon atoms joined to form one or more rings.
- the alicyclic groups may be unsubstituted or substituted. See above for examples of substituents.
- Cycloalkyl is intended to include saturated ring groups, such as cyclopropyl, cyclobutyl, or cyclopentyl. This term is not limited to a monovalent radical.
- the cycloalkyl groups may be unsubstituted or substituted. See above for examples of substituents.
- alkenyl refers to normal alkenyl, branch chain alkenyl and cycloalkenyl groups having one or more sites of unsaturation.
- Alkynyl is intended to include hydrocarbon chains of either a straight or branched configuration and one or more triple carbon-carbon bonds which may occur in any stable point along the chain, such as ethynyl and propynyl. These terms are not limited to monovalent radicals.
- the alkenyl or alkynyl groups may be unsubstituted or substituted. See above for examples of substituents.
- “Lower alkyl” means the above-defined broad definition of alkyl groups having 1 to 6 carbons in case of normal lower alkyl, and as applicable 3 to 6 carbons for lower branch chained (e.g., 2-methyl-propane) and cycloalkyl groups.
- “Lower alkenyl” is defined similarly having 2 to 6 carbons for normal lower alkenyl groups, and 3 to 6 carbons for branch chained and cyclo-lower alkenyl groups.
- “Lower alkynyl” is also defined similarly, having 2 to 6 carbons for normal lower allynyl groups, and 4 to 6 carbons for branch chained lower alkynyl groups.
- the lower alkyl, alkenyl and alkynyl groups may be unsubstituted or substituted. See above for examples of substituents.
- haloalkyl is not limited to a monovalent radical.
- Halogen includes fluorine, chlorine, bromine, iodine and astatine. Examples of haloalkyl include, but are not limited to, trifluoromethyl, trichloromethyl, pentafluoroethyl, and pentachloroethyl.
- heterocyclic refers to any compound in which the ring structure is a combination of more than one kind of atom.
- heterocyclic compounds include, but are not limited to, pyridine, furan and pyrrole. This term is not limited to a monovalent radical.
- the heterocyclic groups may be unsubstituted or substituted. See above for definition of substituents.
- prodrug means a precursor or derivative form of a pharmaceutically active agent or substance that is less cytotoxic to a target cell as compared to the drug metabolite and is capable of being enzymatically activated or converted into the more active form.
- composition is intended to mean a combination of active agent and another compound or composition, inert (for example, a surface, a paint, a detectable agent or label or a pharmaceutically acceptable carrier) or active, such as an adjuvant or disinfectant.
- inert for example, a surface, a paint, a detectable agent or label or a pharmaceutically acceptable carrier
- active such as an adjuvant or disinfectant.
- a “pharmaceutical composition” is intended to include the combination of an active agent with a carrier, inert or active, making the composition suitable for diagnostic or therapeutic use in vitro, in vivo or ex vivo.
- prophylactically effective amount refers to an amount effective in preventing infection in a subject or plant infestation.
- pharmaceutically acceptable carrier and “biologically acceptable carrier” refer to a carrier or adjuvant that is administered to a host or patient, together with a compound of this invention, and which does not destroy the pharmacological activity thereof and is non-toxic, when administered in doses sufficient to deliver an effective amount of the compound.
- suitable carriers include liquid phase carriers, such as sterile or aqueous solutions, as well as those described below.
- pharmaceutically acceptable carrier include any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, water, and emulsions, such as an oil/water or water/oil emulsion, and various types of wetting agents.
- the compositions also can include stabilizers and preservatives. For examples of carriers, stabilizers and adjuvants, see Martin, REMINGTON'S PHARM. SCI., 15th Ed. (Mack Publ. Co., Easton (1975)).
- treating refers to any of the following: the alleviation of symptoms of a particular disorder in a patient; the improvement of an ascertainable measurement associated with a particular disorder; or a reduction in microbial number.
- One of skill in the art can determine when a host has been “treated” by noting a reduction in microbial load or an alleviation in symptoms associated with infection.
- pharmaceutically acceptable salt, prodrug or derivative relates to any pharmaceutically acceptable salt, ester, ether, salt of an ester, solvate, such as ethanolate, or other derivative of a compound of the present invention which, upon administration to a recipient, is capable of providing (directly or indirectly) a compound of this invention or an active metabolite or residue thereof.
- Particularly favored derivatives and prodrugs are those that increase the bioavailability of the compounds of this invention when such compounds are administered to a mammal (e.g., by allowing an orally administered compound to be more readily absorbed into the blood) or which enhance delivery of the parent compound to a biological compartment (e.g., the brain or lymphatic system).
- Salts of the compounds of the present invention may be derived from inorganic or organic acids and bases.
- acids include hydrochloric, hydrobromic, sulfuric, nitric, perchloric, fumaric, maleic, phosphoric, glycolic, lactic, salicylic, succinic, toluene-p-sulfonic, tartaric, acetic, citric, methanesulfonic, ethanesulfonic, formic, benzoic, malonic, naphthalene-2-sulfonic and benzenesulfonic acids.
- acids such as oxalic, while not in themselves pharmaceutically acceptable, may be employed in the preparation of salts useful as intermediates in obtaining the compounds of the invention and their pharmaceutically acceptable acid addition salts.
- bases include alkali metal (e.g., sodium) hydroxides, alkaline earth metal (e.g., magnesium) hydroxides, ammonia, compounds of formula NW 4 + , wherein W is C 1-4 alkyl and THAM (2-amino-2-hydroxymethyl-1,3-propanediol).
- salts include: acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, flucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, palmoate, pectinate, persulfate, phenylproprionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate and unde
- salts of the compounds of the present invention will be pharmaceutically acceptable.
- salts of acids and bases which are non-pharmaceutically acceptable may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound or for use to reduce microbial infestation in plants.
- traceless linker indicates a spacer or connector between two parts of a single molecule such that when a particular bond is severed between the two parts of the molecule, the connector which is still attached to the second part of the molecule, eliminates leaving no trace of itself.
- the term “effective amount” is to include therapeutically or prophylactically effective amounts.
- the term refers to an amount effective in treating or preventing an infection in a patient or an infestation in a plant either as monotherapy or in combination with other agents.
- “Inhibiting the growth” of a microorganism means reducing by contact with an agent, the rate of proliferation of such a microorganism, in comparison with a control microorganism of the same species not contacted with this agent.
- a “subject” is any living entity, plant or animal, that is or can be a direct or indirect host to a PDF expressing microorganism.
- crops such as corn, soybeans, grains, ornamental plants, trees, etc. are subjects within the scope of this invention as are animals such as, also without limitation, fish, shellfish, birds, mammals, and humans.
- Mammals include, but are not limited to, rodents, simians, farm animals, sport animals, pets and humans.
- Toxin 1 and Toxin 2 are each an agent that is toxic upon activation by an activating enzyme, and may be the same or different. More generally, they each refer to any chemical entity useful to treat or prevent harm to plants or animals caused by pathogenic organisms that express PDF. Such chemical entities include, without limitation, anthelmintics, antibacterials including both antibiotics and synthetic compounds, antifungals, antineoplastics, antiprotozoal and the like. It is understood that the, in one aspect, either or both “Toxins” may include B 3 , B 4 , B 5 or B 6 depending on the structure of the prodrug and the mechanism of release of the active species from it. An example of this is seen in FIG.
- Toxin 1 and Toxin 2 are aminoglycosides, mitomycin, CC-1065, ducarmycin, cyclopropyl indole, cyclopropyl benzoindole analogs, anthracyclins, vinca alkaloids, mitomycins, bleomycins, penicillins, cephalosporins, oxacillins, carbopenems, tetracyclins, chloramphenicols, macrolides, cycloserines, fluoroquinolones (including, but not limited to, ciprofloxacin and norfloxacin), glycopeptides, aminoglycosides, peptide antibiotics, oxazolidinones, quinolones, sulfonamides,
- PDF is a perfect ECTA target enzyme. It is active in bacteria and inactive in human hosts. It has broad substrate specificity. Deformylation liberates a free amino group of methionine (or another amino acid or an amino acid analog tolerated as an R 3 of the substrate, such as norleucine) which can perform a subsequent nucleophilic attack. With a rationally designed dipeptide or an equivalent peptidomimetic fragment of the substrate the free amino group can attack an optimally positioned phosphorus of the substrate thus forming a cyclic molecule and releasing a toxin. The substrate can be optimized to enhance cyclization.
- the scheme of the proposed reaction exemplifying a dipeptide-based substrate is given in FIG. 1 .
- X can be, for example, sulfur (methionine) or —CH 2 — (norleucine).
- R 1 and R 2 are aliphatic radicals that can be selected based on the published SAR data for PDF. Hu et al. (1998).
- This invention also provides a composition comprising the prodrug compounds as described above, alone or in combination with other compounds or other agents, known or yet to be discovered, and a carrier.
- the carrier is another molecule or an inert substance such as a plate or column.
- the carrier is a pharmaceutically acceptable carrier.
- Pharmaceutically acceptable carriers are known in the art and described briefly above.
- This invention also provides a composition
- a composition comprising the prodrug compounds as described above, alone or in combination with other compounds or other agents, known or yet to be discovered, and a carrier.
- a carrier such as a pharmaceutically acceptable carrier, and/or an additional effective agent such as an antibiotic.
- Also provided by this invention is a method for inhibiting the growth of a PDF expressing microorganism by contacting the microorganism with an effective amount of the compound as described above.
- Methods to detect PDF expression are known in the art. See, for example, Wei, et al. (1997).
- This method is particularly useful in inhibiting the growth of gram-positive and gram-negative microorganisms, e.g., S. aureus, S. epidermidis, K. pneumoniae, E. aerogenes, E. cloacae, M. catarrhalis, E. coli, E. faecalis, H. influenzae and P. aeruginosa. and those identified in Table 2, below.
- This method can be practiced in vitro, ex vivo and in vivo. Further provided is a method for alleviating the symptoms of an infection in a subject, wherein the infection is caused by a PDF expressing microorganism, by administering or delivering to the subject an effective amount of the compound described above. Also provided by this invention is a method for treating an infection caused by a PDF expressing microorganism by administering or delivering to the subject an effective amount of the compound described above.
- a “subject” is defined above and includes mammals such as human patients. Examples of PDF expressing microorganims and the corresponding diseases and symptoms caused by infection by these microorganisms, are provided in Table 2, below.
- prodrug In the clinical use of the prodrug, antibiotics will likely follow well established guidelines. Dosage will likely be similar to those already employed for most other antibiotics. It is estimated that a dose of prodrug will be in the range of 100 ⁇ g to 100 mg to 1 gm, or given once every eight hours, or once a day, for one or two weeks, or until the patient tests negative for infectious organisms.
- the compounds of this invention are expected to be administered in doses that reflect the literature doses for the active compounds of which they are prodrugs, with the difference in molecular weight being taken into account.
- the dosage for a prodrug hereof will typically be in the range of 100 ⁇ g to 100 mg to 1 gm.
- the invention encompasses a method of treating or protecting plants from infections caused by PDF expressing microorganisms by applying an effective amount of the substrate prodrug.
- This invention also provides a method for treating or protecting plants from infection by microorganisms expressing PDF by applying an effective amount of the prodrug compound to the foliage, roots or the soil surrounding the plants or roots.
- These isolated compounds can be combined with known pesticides or insecticides.
- Compounds within the present invention when used to treat or protect plants from infections caused by PDF expressing microorganisms can be formulated as wettable powders, granules and the like, or can be microencapsulated in a suitable medium and the like.
- suitable medium and the like examples include, but are not limited to soluble powders, wettable granules, dry flowables, aqueous flowables, wettable dispersible granules, emulsifiable concentrates and aqueous suspensions.
- Other suitable formulations will be known to those skilled in the art.
- This invention further provides a method for administering the prodrug compound to fish in an amount effective to either prevent or treat an infection caused by PDF expressing microorganisms.
- the compound may be administered by incorporating the compound into the food supply for the fish. Alternatively, the compound may be added to the water in which fish live, or are contained within. Finally, the compound may be administered to the fish as a suitable pharmaceutical preparation. Other suitable formulations will be known to those skilled in the art. Further provided is a process for producing the prodrugs of this invention. In general the process requires the following steps:
- X can be sulfur (methionine) or —CH 2 — (norleucine).
- R can be R 5 or R 6 as defined above. Reaction conditions and full names for the abbreviations can be found in the experimental examples infra.
- This invention provides a method for identifying potential therapeutic agents that inhibit the growth of an organism expressing PDF by contacting a sample containing the PDF expressing microorganism with an effective amount of a candidate prodrug compound. In a separate sample, the same microorganism is contacted with an effective amount of a prodrug of this invention. If the agent has comparable anti-proliferative ability as compared to a prodrug as described herein, the candidate is useful to inhibit the growth of or kill a PDF-expressing microorganism.
- the prodrug is contacted with the sample under conditions that favor the activation of the prodrug by PDF and then the sample is assayed for growth inhibition or microbial death.
- the sample can be tested for the presence of the byproducts of the reaction of PDF on the substrate. Varying amounts of the substrate are contacted with a microorganism that expresses PDF for an amount of time effective for PDF to release the toxin; from the cell, the bacteria is lysed and the analytes are analyzed using methods known in the art (e.g., High Performance Liquid Chromatography (“HPLC”)) to identify the reaction products.
- HPLC High Performance Liquid Chromatography
- Varying concentrations of the potential agent are contacted with the sample to determine the optimal effective concentration of the agent.
- this invention relates to the discovery, and use thereof, of agents that are selective substrates for PDF.
- kits containing the prodrugs as described herein and instructions necessary to perform the screen are also provided by this invention.
- the methods of the invention can be practiced in vitro, ex vivo or in vivo.
- In vivo practice of the invention in an animal such as a rat or mouse provides a convenient animal model system that can be used prior to clinical testing of the therapeutic agent or prodrug.
- a potential prodrug will be successful if microbial load is reduced or the symptoms of the infection are ameliorated compared to an untreated, infected animal. It also can be useful to have a separate negative control group of cells or animals which has not been infected, which provides a basis for comparison.
- the candidate prodrug When practiced in vivo, the candidate prodrug is administered or delivered to the animal in effective amounts.
- the term “administering” for in vivo and ex vivo purposes means providing the subject with an effective amount of the candidate prodrug effective to reduce microbial load.
- the agent or prodrug may be administered with a pharmaceutically acceptable carrier.
- the agents, prodrugs and compositions of the present invention can be used in the manufacture of medicaments and for the treatment of humans and other animals by administration in accordance with conventional procedures, such as an active ingredient in pharmaceutical compositions.
- compositions are known to those of ordinary skill in the art and include, but are not limited to, microinjection, intravenous or parenteral administration.
- the compositions are intended for topical, oral, or local as well as intravenous, subcutaneous and intramuscular administration. Administration can be effected continuously or intermittently throughout the course of the treatment. Methods of determining the most effective means and dosage of administration are known to those of skill in the art and will vary with the prodrug used for therapy, the purpose of the therapy, the microorganism being treated, the severity of the infection, and the subject being treated. Single or multiple administrations can be carried out with the dose level and pattern being selected by the treating physician.
- the compositions can be administered to a subject already suffering from an antibiotic resistant bacterial infection. In this situation, an effective “therapeutic amount” of the composition is administered to prevent continued and to at least partially arrest microbial growth and proliferation and ameliorate the symptoms associated with an infection.
- the prodrugs can be administered to subjects or individuals susceptible to or at risk of developing an infection.
- a “prophylactically effective amount” of the composition is administered to maintain cell viability and function at a level near to the pre-infection level.
- Administration in vivo can be effected in one dose, continuously or intermittently throughout the course of treatment. Methods of determining the most effective means and dosage of administration are known to those of skill in the art and will vary with the composition used for therapy, the purpose of the therapy, the target cell being treated, and the subject being treated. Single or multiple administrations can be carried out with the dose level and pattern being selected by the treating physician. Suitable dosage formulations and methods of administering the agents can be found below.
- the pharmaceutical compositions can be administered orally, intranasally, parenterally or by inhalation therapy, and may take the form of tablets, lozenges, granules, capsules, pills, ampoules, suppositories or aerosol form. They may also take the form of suspensions, solutions and emulsions of the active ingredient in aqueous or nonaqueous diluents, syrups, granulates or powders. In addition to an agent of the present invention, the pharmaceutical compositions can also contain other pharmaceutically active compounds or a plurality of compounds of the invention.
- an agent of the present invention also referred to herein as the active ingredient, may be administered for therapy by any suitable route including oral, rectal, nasal, topical (including transdermal, aerosol, buccal and sublingual), vaginal, parenteral (including subcutaneous, intramuscular, intravenous and intradermal) and pulmonary. It will also be appreciated that the route will vary with the condition and age of the recipient, and the disease being treated.
- the agent should be. administered to achieve peak concentrations of the active compound at sites of disease. This may be achieved, for example, by the intravenous injection of the agent, optionally in saline, or orally administered, for example, as a tablet, capsule or syrup containing the active ingredient. Desirable blood levels of the agent may be maintained by a continuous infusion to provide a therapeutic amount of the active ingredient within disease tissue.
- operative combinations is contemplated to provide therapeutic combinations requiring a lower total dosage of each component agent than may be required when each individual therapeutic compound or drug is used alone, thereby reducing adverse effects.
- the agent While it is possible for the agent to be administered alone, it is typical to present it as a pharmaceutical formulation comprising at least one active ingredient, as defined above, together with one or more pharmaceutically acceptable carriers therefor and optionally other therapeutic agents.
- Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient.
- Formulations include those suitable for oral, rectal, nasal, topical (including transdermal, buccal and sublingual), vaginal, parenteral (including subcutaneous, intramuscular, intravenous and intradermal) and pulmonary administration.
- the formulations may conveniently be presented in unit dosage form and may be prepared by any methods known in the art of pharmacy. Such methods include the step of bringing into association the active ingredient with the carrier that constitutes one or more accessory ingredients.
- the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then if necessary shaping the product.
- Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets, each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or suspension in an aqueous or non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion.
- the active ingredient may also be presented as a bolus, electuary or paste.
- a tablet may be made by compression or molding, optionally with one or more accessory ingredients.
- Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder (e.g., povidone, gelatin, hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (e.g., sodium starch glycolate, cross-linked povidone, cross-linked sodium carboxymethyl cellulose) surface-active or dispersing agent.
- Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
- the tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile. Tablets may optionally be provided with an enteric coating, to provide release in parts of the gut other than the stomach.
- Formulations suitable for topical administration in the mouth include lozenges comprising the active ingredient in a flavored basis, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
- compositions for topical administration may be formulated as an ointment, cream, suspension, lotion, powder, solution, past, gel, spray, aerosol or oil.
- a formulation may comprise a patch or a dressing such as a bandage or adhesive plaster impregnated with active ingredients and optionally one or more excipients or diluents.
- the aqueous phase of the cream base may include, for example, at least about 30% w/w of a polyhydric alcohol, i.e., an alcohol having two or more hydroxyl groups such as propylene glycol, butane-1,3-diol, mannitol, sorbitol, glycerol and polyethylene glycol and mixtures thereof.
- the topical formulations may desirably include a compound that enhances absorption or penetration of the agent through the skin or other affected areas. Examples of such dermal penetration enhancers include dimethylsulfoxide and related analogues.
- the oily phase of the emulsions of this invention may be constituted from known ingredients in a known manner. While this phase may comprise merely an emulsifier (otherwise known as an emulgent), it desirably comprises a mixture of at lease one emulsifier with a fat or an oil or with both a fat and an oil.
- emulsifier alsowise known as an emulgent
- a hydrophilic emulsifier can be included together with a lipophilic emulsifier that acts as a stabilizer.
- it includes both an oil and a fat.
- the emulsifier(s) with or without stabilizer(s) make up the so-called emulsifying wax
- the wax together with the oil and/or fat make up the so-called emulsifying ointment base which forms the oily dispersed phase of the cream formulations.
- Emulgents and emulsion stabilizers suitable for use in the formulation of the present invention include Tween 60, Span 80, cetostearyl alcohol, myristyl alcohol, glyceryl monostearate and sodium lauryl sulfate.
- the choice of suitable oils or fats for the formulation is based on achieving the desired cosmetic properties, since the solubility of the active compound in most oils likely to be used in pharmaceutical emulsion formulations is very low.
- the cream can be a non-greasy, non-staining and washable product with suitable consistency to avoid leakage from tubes or other containers.
- Straight or branched chain, mono- or dibasic alkyl esters such as di-isoadipate, isocetyl stearate, propylene glycol diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a blend of branched chain esters known as Crodamol CAP may be used. These may be used alone or in combination depending on the properties required. Alternatively, high melting point lipids such as white soft paraffin and/or liquid paraffin or other mineral oils can be used.
- Formulations suitable for topical administration to the eye also include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent for the agent.
- Formulations for rectal administration may be presented as a suppository with a suitable base comprising, for example, cocoa butter or a salicylate.
- Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the agent, such carriers as are known in the art to be appropriate.
- Formulations suitable for nasal administration wherein the carrier is a solid, include a coarse powder having a particle size, for example, in the range of about 20 to about 500 microns which is administered as a dry powder or in an inhaler device by rapid inhalation through the nasal passage from a container of the powder held close up to the nose.
- Suitable formulations wherein the carrier is a liquid for administration as, for example, nasal spray, nasal drops, or by aerosol administration by nebulizer include aqueous or oily solutions of the agent.
- Formulations suitable for parenteral administration include aqueous and non-aqueous isotonic sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents, and liposomes or other microparticulate systems which are designed to target the compound to blood components or one or more organs.
- the formulations may be presented in unit-dose or multi-dose sealed containers, for example, ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use.
- Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
- Unit dosage formulations of interest include those containing a daily dose or unit, daily subdose, as herein above-recited, or an appropriate fraction thereof, of a agent.
- formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question, for example, those suitable for oral administration may include such further agents as sweeteners, thickeners and flavoring agents. It also is intended that the agents, compositions and methods of this invention be combined with other suitable compositions and therapies.
- both the racemic mixture and enantiomerically enhanced (i.e., one entantiomer exists in greater than 50% of the mixture) or enantiomerically pure (one enantiomer comprises 90% or more of the mixture) compounds are within the scope of this invention.
- the crude phosphonochloridate was then redissolved in anhydrous dichloromethane (5 mL) and the mixture was added dropwise, at 0° C., to a stirring solution of triclosan (1.07 g., 1 eq.) and anhydrous triethyalmine (520 ul, 1 eq.) in anhydrous dichloromethane (5 mL).
- the reaction mixture was allowed to warm up to room temperature and was stirred under argon atmosphere for 1 hour.
- the reaction mixture was then extracted with water (10 mL).
- the organic phase was dried over sodium sulfate for 30 minutes.
Abstract
Description
- This application claims the benefit under 35 U.S.C. § 119(e) of U.S. Provisional Application No. 60/426,771, filed Nov. 14, 2002, the contents of which hereby incorporated by reference into the present disclosure.
- The present invention relates to the field of Enzyme Catalyzed Therapeutic Activation (ECTA™) therapy and in particular, ECTA therapies specific for microorganisms that express Peptide Deformylase (“PDF”).
- Throughout this disclosure, various publications are referenced by first author and date, within parentheses, patent number or publication number. The complete bibliographic reference is given at the end of the application. The disclosures of these references are hereby incorporated by reference into this disclosure to more fully describe the state of the art to which this application pertains.
- Enzyme Catalyzed Therapeutic Activation (ECTA™) therapy is a novel technology that provides unique prodrug substrates for target enzymes. Unlike conventional therapies, ECTA prodrugs neither inhibit nor irreversibly inactivate the target enzyme. U.S. Pat. Nos. 6,159,706; 6,245,750 and 6,339,151B1. See also PCT/US98/16607; PCT/US99/01332; and PCT/US00/20008.
- Target enzymes convert the ECTA prodrug into a toxin preferentially within the target cell or in an environment wherein the target enzyme is expressed as compared to an environment where it is absent, as in an infected cell. Because the compounds do not require a targeting agent, they can be directly utilized, topically or systemically.
- ECTA molecules do not, in most instances, yield cytotoxic products spontaneously (without target enzyme activation). They are not be appreciably activated by non-targeted enzymes, as this may result in toxicity to non-diseased or non-infected tissue. Table 1 summarizes the characteristics of ECTA molecules and enzyme activators.
TABLE 1 Characteristics of ECTA Target Enzymes Characteristics of ECTA Prodrugs Infectious Disease: Must be present Must be able to get into cells (by only in target cells (including itself or as prodrug). diseased cells, bacteria, fungi, etc.). The enzyme should be necessary for continued viability or pathogenicity. Must process a molecule that At least one of the products formed resembles the natural substrate (an from the enzymatic reaction must ECTA molecule) into cytotoxic be cytotoxic. However, the ECTA species. The resemblance only has to remain in inactive form until be significant with respect to the activated by the target enzyme. specificity of the enzyme/substrate The compound must have a high interaction and the ability of the degree of specificity for the enzyme to process the substrate targeted enzyme, although intracellularly into toxic species. conversion by a non-targeted enzyme is acceptable if the product(s) are not cytotoxic. Must not be inactivated by the ECTA Must not inhibit or deactivate the molecule, intermediate(s), or the targeted enzyme. product(s) of the reaction. - In cases of bacterial, viral and fungal infections in plants, people or agriculturally important animals, metabolic pathways being present in the pathogenic organisms, but absent in the host are a source of potential ECTA target enzymes. For example, some pathways, as well as the enzymes involved, have only been found in bacteria, fungi and plants and not in mammalian cells. One example is the synthesis of “essential” amino acids—amino acids that animals cannot synthesize and must ingest with food. Nelson and Cox (1972).
- Another example is Peptide Deformylase (“PDF”, EC 3.5.1.88) which catalyses deformylation of N-terminal N-formyl methionine in a growing polypeptide chain. Meinnel (1999). The enzyme is present and active in bacteria (Meinnel et al, 1993), but has not been reported to be active in mammalian cells. Sequences homologous to bacterial PDF sequences have been recently found in mammals but their exact function is unknown. Giglione (2000a) and (2000b).
- Because the enzyme is not active in humans it has been used as a target for antibacterial drugs, mostly PDF inhibitors. Dithiols can act as non-specific PDF inhibitors by coordination of sulfhydryl groups with the active site metal ion. Rajagopalan (1997). In case of 1,2- or 1,3-dithiols a slow extraction of the metal ion from the active site takes place. The formation of stable 5- or 6-membered rings, respectively, each containing two metal-sulfur bonds, accounts for this effect.
- A rationally designed combinatorial library was used to select mechanism-based PDF inhibitors of the general structure HS—CH2—CH(Ra)—CONH—CH(Rb)—CONH—Rc. Wei et al. (2000a). The optimal inhibitor selected from the library possesses an n-Bu group as an Ra, Rb═—(CH2)3—NH—C(═NH)—NH2, and Rc is 2-naphthalene. This compound acts as a competitive PDF inhibitor with a Ki of 15 nM.
- Jayasekera et al. (2000) describes a series of non-peptidic compounds structurally related to the known anticholesteremic thyropropic acid to inhibit E. coli PDF. Actinonin is reported to be a potent PDF inhibitor with activity in the subnanomolar Ki range. Chen (2000) and Guilloteau et al (2002).
- Wei, et al. (2000a) describe that 5′-dipeptidyl derivatives of 5-fluorodeoxyuridine release a small molecule (5-fluorodeoxyuridine (5-F-dUrd)) upon PDF catalyzed deformylation. 5-F-dUrd formation was monitored in the reaction of the substrate catalyzed by purified PDF or E. coli crude lysates. The compound was marginally cytotoxic (IC50>100 μM) when applied to E. coli bacteria. Potency was not increased by increased expression of PDF in bacteria (using a PDF-overexpressing strain). The compound was slightly more effective (IC50=50 μM) against gram-positive microorgansims.
- Additional inhibitors are described in Apfel et al. (2000), Apfel et al. (2001 a), Apfel et al. (2001b), Clements et al. (2001), Durand et al. (1999), Chen et al. (2000), Yuan et al (2001), and Wise et al (2002)
- However, a compound or agent that is not an inhibitor but rather selectively and effectively activated by PDF to a toxin has not been described. This invention satisfies this need and provides related advantages as well.
-
- R1 is hydrogen or CH3;
- R4 is selected from the group consisting of a substituted or unsubstituted aryl group, a substituted or unsubstituted, saturated or unsaturated C1-C6 alkyl group and CH2CH2XCH3, wherein X is selected from the group consisting of oxygen, sulfur and CH2;
- R5 and R6 are independently selected from the group consisting of hydrogen, a substituted or unsubstituted C5-C14 aryl group and a substituted or unsubstituted, saturated or unsaturated C1-C6 alkyl group;
- =A1 is either absent, in which case the carbon to which it was attached becomes a CH2 group, or A1 is selected from the group consisting of oxygen, sulfur, NH, NOH, NR8, and CR9R10, wherein R8, R9 and R10 are independently selected from the group consisting of hydrogen and C1-C6 alkyl;
- =A2 is either absent, in which case the carbon to which it was attached becomes a CH2 group, or A2 is selected from the group consisting of oxygen, sulfur, NH, NOH and NR11 wherein R11 is selected from the group consisting of hydrogen and C1-C6 alkyl;
- B1is either absent or is selected from the group consisting of oxygen, sulfur, NR12 and CR13R14, wherein R12 R13 and R14 are independently selected from the group consisting of hydrogen and a substituted or unsubstituted saturated or unsaturated alkyl;
- B2 is selected from the group consisting of carbon, oxygen and nitrogen, wherein, when B2 is oxygen, R5 and R6 are absent and when B2 is nitrogen, one of R5 or R6 is absent;
- B1 may be joined through R12, R13 or R14 to R5 or R6 to form a saturated or unsaturated, substituted or unsubstituted ring which may contain 0-3 nitrogen atoms and/or 0-1 oxygen or sulfur atoms;
- B3 and B4 are independently the same or different and are absent or are selected from the group consisting of oxygen, sulfur, NH, CH2, NR17, CHR18, CR21R22 and, when either linker1-B5-Toxin1 or linker2-B6-Toxin2 is absent, OR15, SR16, NR19R20 and CR23R24R25, wherein R15—R25 are independently selected from the group consisting of hydrogen, substituted or unsubstituted, saturated or unsaturated alkyl and substituted or unsubstituted aryl;
- B3 or B4 may be joined through one of R15—R25 to B1, R5 or R6 to form a saturated or unsaturated, substituted or unsubstituted ring which contains one phosphorus atom and which may contain 0-3 nitrogen atoms and/or 0-1 oxygen or sulfur atoms;
- B5 and B6 are independently the same or different and are absent or are selected from the group consisting of oxygen, sulfur, OC(═O), SC(═S), OC(═O)NH, SC(═S)NH, OC(═S)NH, N(R26) and C(R27)(R28), wherein R26, R27 and R28 are independently selected from the group consisting of hydrogen and a substituted or unsubstituted, saturated or unsaturated alkyl;
- Linker1 and Linker2 are independently the same or different and are absent or present and, if present, are traceless; and,
- one of Toxin1 or Toxin2 may be absent.
- In an aspect of this invention, R1 is hydrogen and R4 is CH2CH2XCH3, and X is selected from the group consisting of CH2, sulfur and oxygen.
- In an aspect of this invention, X is sulfur.
- In an aspect of this invention, A1 and A2 are both oxygen.
- In an aspect of this invention, Linker1-B5-Toxin1 is absent.
- In an aspect of this invention, B1 is absent.
- In an aspect of this invention B2 is carbon.
- In an aspect of this invention, B2 is nitrogen.
- In an aspect of this invention, B3 is selected from the group consisting of OH, OCH3, OCH2CH3 and OC6H5.
- In an aspect of this invention, Linker2 is selected from the group consisting of
- substituted or unsubstituted allyl;
- substituted or unsubstituted benzyl;
- C6H4CH2X1C(═X2), wherein X1 and X2 are independently selected from the group consisting of oxygen, sulfur and N(R29), wherein R29 is hydrogen or C1-C6 alkyl; and, (CH2)nN(R)C(═O), wherein n is 2 or 3 and R is hydrogen or C1-C6 alkyl.
- In an aspect of this invention B6 is absent.
- In an aspect of this invention, in any of the above compounds, Toxin1 and Toxin2 are independently selected from the group consisting of aminoglycosides, mitomycin, CC-1065, ducarmycin, cyclopropyl indole, cyclopropyl benzoindole analogs, anthracyclins, vinca alkaloids, mitomycins, bleomycins, penicillins, cephalosporins, oxacillins, carbopenems, tetracyclins, chloramphenicols, macrolides, cycliserines, fluoroquinolones (including, but not limited to, ciprofloxacin and norfloxacin), glycopeptides, aminoglycosides, peptide antibiotics, oxazolidinones, quinolones, sulfonamides, cytotoxic nucleosides, pteridine family, nitrogen mustards, polyhalogenated biaryl ethers, diynenes, podophillotoxins, taxoids, doxorubicin, carminomycin, daunorubicin, aminopterin, methotrexate, methopterin, dichloromethotrexate, mitomycin C, porfiromycin, 6-mercaptopurine, cytosine arabinoside, podophillotoxin, etoposide,. etoposide phosphate, melphalan, vindesine, vinblastine, vincristine, leurosidine, leurosine, bis-(2-chloroethyl)amine, trichlorcarban, trichlorocarbanilide, triclosan, tribromosalicylanilide, sulphamethoxazole, chloramphenicol, cycloserine, trimethoprim, chlorhexidine, hexachlorophene, fentichlor, 5-chloro-2-(2,4-dichlorophenoxy)phenol, 4-chloro-2-(2,4-dichlorophenoxy)phenol, 3-chloro-2-(2,4-dichlorophenoxy)phenol, 6-chloro-2-(2,4-dichlorophenoxy)phenol, 5-chloro-2-(3,4-dichlorophenoxy)phenol, 5-chloro-2-(2,5-dichlorophenoxy)phenol, 5-chloro-2-(3,5-dichlorophenoxy)phenol, 2,2′-dihydroxy biphenyl ether, halogenated 2-hydroxybenzophenones, 2-mercaptopyridine-N-oxide, combretastatin, camptothesin, apoptolidene, cisplatin, epothilone, halichondrin, hemiasterlin, methioprim, thapsigargin, chloroquine, 4-hydroxycyclophosphamide, etoposide, colchicine, melphalan, quercetin, genistein, erbstatin, N-(4-aminobutyl)-5-chloro-2-naphtalen-sulfonamide, pyridinyloxazol-2-one, isoquinolyloxazolone-2-one, verapamil, quinine, quinidine, and chloroquine.
- In an aspect of this invention, Toxin2 is a quinolone.
- In an aspect of this invention, Toxin2 is selected from the group consisting of triclosan, cyclopropylindole, cyclopropylbenzoindole and derivatives thereof.
- In an aspect of this invention, B1 is joined to R5 or R6 to form a ring.
-
- An aspect of this invention is a composition comprising a compound hereof and a pharmaceutically acceptable carrier.
- An aspect of this invention is a method for the treatment of a disease caused by a microorganism expressing a peptide deformylase enzyme, comprising administering an effective amount of a compound of claim 1 to a subject in need thereof.
- Also provided by this invention is a method for inhibiting the growth of a microorganism that expresses PDF by contacting the microorganism with an effective amount of the compound as describe above. This method inhibits the growth of a gram-positive or gram-negative microorganism, e.g., of S. aureus, S. epidermidis, K. pneumoniae, E. aerogenes, E. cloacae, M. catarrhalis, E. coli, E. faecalis, H. influenzae or P. aeruginosa. This method can be practiced in vitro, ex vivo and in vivo. Further provided is a method for alleviating the symptoms of an infection by a PDF expressing microorganism in a subject by administering or delivering to the subject an effective amount of the compound described above. A “subject” is defined herein and includes mammals such as human patients.
- This invention also provides a composition comprising the prodrug compounds as described above, alone or in combination with other compounds or other agents, known or yet to be discovered, and a carrier. In one aspect, the carrier is another molecule or an inert substance such as a plate or column. In an alternative embodiment, the carrier is a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers are known in the art and described briefly above.
- Brief Description of the Table
- Table 1 shows a list of non-limiting charactertistics of ECTA target enzymes and ECTA prodrugs.
- Table 2 is a non-limiting list of bacteria that express PDF and therefore are expected to be susceptible to the compounds of this invention.
-
FIG. 1 is a proposed reaction scheme for PDF activation of the compounds of this invention. - The practice of the present invention will employ, unless otherwise indicated, conventional techniques of organic chemistry, pharmacology, molecular biology (including recombinant techniques), cell biology, biochemistry, and immunology, which are within the skill of the art. Such techniques are explained fully in the literature, such as, “
MOLECULAR CLONING: A LABORATORY MANUAL ” Second Edition (Sambrook et al., 1989); “OLIGONUCLEOTIDE SYNTHESIS ” (M. J. Gait, ed., 1984); “ANIMAL CELL CULTURE ” (R. I. Freshney, ed., 1987); the series “METHODS IN ENZYMOLOGY ” (Academic Press, Inc.); “HANDBOOK OF EXPERIMENTAL IMMUNOLOGY ” (D. M. Weir & C. C. Blackwell, eds.); “GENE TRANSFER VECTORS FOR MAMMALIAN CELLS ” (J. M. Miller & M. P. Calos, eds., 1987); “CURRENT PROTOCOLS IN MOLECULAR BIOLOGY ” (F. M. Ausubel et al., eds., 1987, and periodic updates); “PCR: THE POLYMERASE CHAIN REACTION ” (Mullis et al., eds., 1994); “CURRENT PROTOCOLS IN IMMUNOLOGY ” (J. E. Coligan et al., eds., 1991); J. March, ADVANCED ORGANIC CHEMISTRY: REACTIONS, MECHANISMS AND STRUCTURE, 4th edition (John Wiley & Sons, NY (1992)). - As used herein, certain terms may have the following defined meanings.
- The singular form “a,” “an” and “the” include plural references unless the context clearly dictates otherwise. For example, the term “a cell” includes a plurality of cells, including mixtures thereof.
- The term “comprising” is intended to mean that the compositions and methods include the recited elements, but do not exclude others. “Consisting essentially of,” when used to define compositions and methods, shall mean excluding other elements of any essential significance to the combination. Thus, a composition consisting essentially of the elements as defined herein would not exclude trace contaminants from the isolation and purification method and pharmaceutically acceptable carriers, such as phosphate buffered saline, preservatives, and the like. “Consisting of” shall mean excluding more than trace elements of other ingredients and substantial method steps for administering the compositions of this invention. Embodiments defined by each of these transition terms are within the scope of this invention.
- As used herein, the term “peptidomimetic” refers to a compound containing non-peptidic structural elements that is capable of mimicking or antagonizing the biological action(s) of a natural parent peptide.
- As used herein, the term “substituents” includes, but is not limited to halogen atoms and halomethyl groups such as CF3 and CCl3; oxygen containing groups such as oxo, hydroxy, carboxy, carboxyalkyl, alkoxy, alkoyl, alkoyloxy, aryloxy, aryloyl, and aryloyloxy; nitrogen containing groups such as amino, alkylamino, dialkylamino, cyano, azide and nitro; sulfur containing groups such as thiol, alkylthiol, sulfonyl and sulfoxide; heterocyclic groups which may themselves be substituted; alkyl groups which may themselves be substituted; and aryl groups which may themselves be substituted.
- The term “alkyl” refers to any branched or unbranched, cyclic or acyclic, saturated (alkyl) or unsaturated (alkenyl or alkynyl) hydrocarbyl radical. This term is not limited to a monovalent radical. Where cyclic, the alkyl group is C3 to C12. Where acyclic, the alkyl group is C1 to C16. The term “alkoxy” and “aryloxy” means alkyl-O and aryl-O groups, respectively. Reference to “alkoyl” and “aryloyl” groups means alkyl-CO and aryl-CO, respectively.
- The term “aryl” refers to an aromatic group, such as phenyl or napthyl, or a heteroatomic group containing one or more heteroatom, such as pyridyl, pyrrolyl, furanyl and thiophenyl. This term is not limited to a monovalent radical. The term “aromatic” refers to any compound characterized by the presence of at least one benzene ring. Examples of aromatic groups include, but are not limited to, benzene and naphthalene.
- The alkyl and aryl groups may be substituted or unsubstituted. The term “aliphatic” refers to any and all organic compounds of hydrogen and carbon characterized by a straight chain of the carbon atoms. The subgroups of “aliphatic” compounds includes alkanes, alkenes, and alkynes. The aliphatic groups may be unsubstituted or substituted. See above for examples of substituents.
- The term “alicyclic” refers to and covers any and all organic compounds of hydrogen and carbon atoms joined to form one or more rings. The alicyclic groups may be unsubstituted or substituted. See above for examples of substituents.
- “Cycloalkyl” is intended to include saturated ring groups, such as cyclopropyl, cyclobutyl, or cyclopentyl. This term is not limited to a monovalent radical. The cycloalkyl groups may be unsubstituted or substituted. See above for examples of substituents.
- The term “alkenyl” refers to normal alkenyl, branch chain alkenyl and cycloalkenyl groups having one or more sites of unsaturation. “Alkynyl” is intended to include hydrocarbon chains of either a straight or branched configuration and one or more triple carbon-carbon bonds which may occur in any stable point along the chain, such as ethynyl and propynyl. These terms are not limited to monovalent radicals. The alkenyl or alkynyl groups may be unsubstituted or substituted. See above for examples of substituents.
- “Lower alkyl” means the above-defined broad definition of alkyl groups having 1 to 6 carbons in case of normal lower alkyl, and as applicable 3 to 6 carbons for lower branch chained (e.g., 2-methyl-propane) and cycloalkyl groups. “Lower alkenyl” is defined similarly having 2 to 6 carbons for normal lower alkenyl groups, and 3 to 6 carbons for branch chained and cyclo-lower alkenyl groups. “Lower alkynyl” is also defined similarly, having 2 to 6 carbons for normal lower allynyl groups, and 4 to 6 carbons for branch chained lower alkynyl groups. The lower alkyl, alkenyl and alkynyl groups may be unsubstituted or substituted. See above for examples of substituents.
- “Haloalkyl” is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms, substituted with 1 or more halogen (for example —CvFw where v=1 to 3 and w=1 to (2v+1)). The term haloalkyl is not limited to a monovalent radical. “Halogen” includes fluorine, chlorine, bromine, iodine and astatine. Examples of haloalkyl include, but are not limited to, trifluoromethyl, trichloromethyl, pentafluoroethyl, and pentachloroethyl.
- The term “heterocyclic” refers to any compound in which the ring structure is a combination of more than one kind of atom. Examples of heterocyclic compounds include, but are not limited to, pyridine, furan and pyrrole. This term is not limited to a monovalent radical. The heterocyclic groups may be unsubstituted or substituted. See above for definition of substituents.
- As used herein the term “prodrug” means a precursor or derivative form of a pharmaceutically active agent or substance that is less cytotoxic to a target cell as compared to the drug metabolite and is capable of being enzymatically activated or converted into the more active form.
- A “composition” is intended to mean a combination of active agent and another compound or composition, inert (for example, a surface, a paint, a detectable agent or label or a pharmaceutically acceptable carrier) or active, such as an adjuvant or disinfectant.
- A “pharmaceutical composition” is intended to include the combination of an active agent with a carrier, inert or active, making the composition suitable for diagnostic or therapeutic use in vitro, in vivo or ex vivo.
- The term “prophylactically effective amount” refers to an amount effective in preventing infection in a subject or plant infestation.
- The term “pharmaceutically acceptable carrier” and “biologically acceptable carrier” refer to a carrier or adjuvant that is administered to a host or patient, together with a compound of this invention, and which does not destroy the pharmacological activity thereof and is non-toxic, when administered in doses sufficient to deliver an effective amount of the compound. Examples of suitable carriers include liquid phase carriers, such as sterile or aqueous solutions, as well as those described below. Examples of pharmaceutically acceptable carrier include any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, water, and emulsions, such as an oil/water or water/oil emulsion, and various types of wetting agents. The compositions also can include stabilizers and preservatives. For examples of carriers, stabilizers and adjuvants, see Martin, REMINGTON'S PHARM. SCI., 15th Ed. (Mack Publ. Co., Easton (1975)).
- The term “treating” refers to any of the following: the alleviation of symptoms of a particular disorder in a patient; the improvement of an ascertainable measurement associated with a particular disorder; or a reduction in microbial number. One of skill in the art can determine when a host has been “treated” by noting a reduction in microbial load or an alleviation in symptoms associated with infection.
- The term “pharmaceutically acceptable salt, prodrug or derivative” relates to any pharmaceutically acceptable salt, ester, ether, salt of an ester, solvate, such as ethanolate, or other derivative of a compound of the present invention which, upon administration to a recipient, is capable of providing (directly or indirectly) a compound of this invention or an active metabolite or residue thereof. Particularly favored derivatives and prodrugs are those that increase the bioavailability of the compounds of this invention when such compounds are administered to a mammal (e.g., by allowing an orally administered compound to be more readily absorbed into the blood) or which enhance delivery of the parent compound to a biological compartment (e.g., the brain or lymphatic system).
- Salts of the compounds of the present invention may be derived from inorganic or organic acids and bases. Examples of acids include hydrochloric, hydrobromic, sulfuric, nitric, perchloric, fumaric, maleic, phosphoric, glycolic, lactic, salicylic, succinic, toluene-p-sulfonic, tartaric, acetic, citric, methanesulfonic, ethanesulfonic, formic, benzoic, malonic, naphthalene-2-sulfonic and benzenesulfonic acids. Other acids, such as oxalic, while not in themselves pharmaceutically acceptable, may be employed in the preparation of salts useful as intermediates in obtaining the compounds of the invention and their pharmaceutically acceptable acid addition salts. Examples of bases include alkali metal (e.g., sodium) hydroxides, alkaline earth metal (e.g., magnesium) hydroxides, ammonia, compounds of formula NW4 +, wherein W is C1-4 alkyl and THAM (2-amino-2-hydroxymethyl-1,3-propanediol).
- Examples of salts include: acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, flucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, palmoate, pectinate, persulfate, phenylproprionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate and undecanoate. Other examples of salts include anions of the compounds of the present invention compounded with a suitable cation such as Na+, Li+, NH4 +, and NW4 + (wherein W is a C1-4 alkyl group).
- For therapeutic use, salts of the compounds of the present invention will be pharmaceutically acceptable. However, salts of acids and bases which are non-pharmaceutically acceptable may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound or for use to reduce microbial infestation in plants.
- The term “traceless linker” indicates a spacer or connector between two parts of a single molecule such that when a particular bond is severed between the two parts of the molecule, the connector which is still attached to the second part of the molecule, eliminates leaving no trace of itself. This may most easily be seen by examining the following non-limiting example:
Once the PDF has deformylated the prodrug to reveal the amine group, the amine nitrogen attacks the phosphorus to form a six-member ring with the resultant elimination of the oxygen-containing group, which in turn undergoes a semiquinone methide rearrangement resulting in the release of the toxin with no remaining trace of the linker moiety itself, the linker thus being “traceless.” Other traceless linkers will be apparent to those skilled in the art based on the disclosure herein and are within the scope of this invention. See, for example, de Groot et al. (2000). - The term “effective amount” is to include therapeutically or prophylactically effective amounts. The term refers to an amount effective in treating or preventing an infection in a patient or an infestation in a plant either as monotherapy or in combination with other agents.
- “Inhibiting the growth” of a microorganism means reducing by contact with an agent, the rate of proliferation of such a microorganism, in comparison with a control microorganism of the same species not contacted with this agent.
- A “subject” is any living entity, plant or animal, that is or can be a direct or indirect host to a PDF expressing microorganism. Thus, without limitation, crops such as corn, soybeans, grains, ornamental plants, trees, etc. are subjects within the scope of this invention as are animals such as, also without limitation, fish, shellfish, birds, mammals, and humans. Mammals include, but are not limited to, rodents, simians, farm animals, sport animals, pets and humans.
- As used herein, “Toxin1 and Toxin2” are each an agent that is toxic upon activation by an activating enzyme, and may be the same or different. More generally, they each refer to any chemical entity useful to treat or prevent harm to plants or animals caused by pathogenic organisms that express PDF. Such chemical entities include, without limitation, anthelmintics, antibacterials including both antibiotics and synthetic compounds, antifungals, antineoplastics, antiprotozoal and the like. It is understood that the, in one aspect, either or both “Toxins” may include B3, B4, B5 or B6 depending on the structure of the prodrug and the mechanism of release of the active species from it. An example of this is seen in
FIG. 1 , wherein the oxygen attached to the “Tox” group is actually a component (as a hydroxyl group) of the actual Toxin, triclosan. Some specific examples of chemical entities that can comprise Toxin1 and Toxin2 are aminoglycosides, mitomycin, CC-1065, ducarmycin, cyclopropyl indole, cyclopropyl benzoindole analogs, anthracyclins, vinca alkaloids, mitomycins, bleomycins, penicillins, cephalosporins, oxacillins, carbopenems, tetracyclins, chloramphenicols, macrolides, cycloserines, fluoroquinolones (including, but not limited to, ciprofloxacin and norfloxacin), glycopeptides, aminoglycosides, peptide antibiotics, oxazolidinones, quinolones, sulfonamides, cytotoxic nucleosides, pteridine family, nitrogen mustards, polyhalogenated biaryl ethers, diynenes, podophillotoxins, taxoids, doxorubicin, carminomycin, daunorubicin, aminopterin, methotrexate, methopterin, dichloromethotrexate, mitomycin C, porfiromycin, 6-mercaptopurine, cytosine arabinoside, podophillotoxin, etoposide, etoposide phosphate, melphalan, vindesine, vinblastine, vincristine, leurosidine, leurosine, bis-(2-chloroethyl)amine, trichlorcarban, trichlorocarbanilide, triclosan, tribromosalicylanilide, sulphamethoxazole, chloramphenicol, cycloserine, trimethoprim, chlorhexidine, hexachlorophene, fentichlor, 5-chloro-2-(2,4-dichlorophenoxy)phenol, 4-chloro-2-(2,4-dichlorophenoxy)phenol, 3-chloro-2-(2,4-dichlorophenoxy)phenol, 6-chloro-2-(2,4-dichlorophenoxy)phenol, 5-chloro-2-(3,4-dichlorophenoxy)phenol, 5-chloro-2-(2,5-dichlorophenoxy)phenol, 5-chloro-2-(3,5-dichlorophenoxy)phenol, 2,2′-dihydroxy biphenyl ether, halogenated 2-hydroxybenzophenones, 2-mercaptopyridine-N-oxide, combretastatin, camptothesin, apoptolidene, cisplatin, epothilone, halichondrin, hemiasterlin, methioprim, thapsigargin, chloroquine, 4-hydroxycyclophosphamide, etoposide, colchicine, melphalan, quercetin, genistein, erbstatin, N-(4-aminobutyl)-5-chloro-2-naphtalen-sulfonamide, pyridinyloxazol-2-one, isoquinolyloxazolone-2-one, verapamil, quinine, quinidine, and chloroquine. - PDF is a well-studied enzyme whose crystallographic structure has been elucidated. Chan et al. (1997). The enzyme has been expressed in E. coli BL21(DE3) cells Rajagopalan et al. (1997). The authors of the paper isolated the E. coli def gene by PCR using the primers designed based on the literature data on the sequence of the gene. The purified enzyme is unstable due to fast oxidation of the catalytic site Fe2+ by atmospheric oxygen. Rajagopalan et al. (1998). The conditions for proper handling of the enzyme to avoid inactivation have been reported. Rajagopalan et al. (1997). Zn2+ and Ni2+ containing PDF's are stable allowing for the in vitro evaluation of the enzyme catalytic properties. There exists a simple continuous colorimetric assay for PDF. Wei et al. (1997). It utilizes N-formylmethionylleucine p-nitroanilide as a substrate. A coupled aminopeptidase reaction that follows the PDF reaction releases p-nitroaniline that can be monitored spectrophotometrically at 405 mm.
- PDF is a perfect ECTA target enzyme. It is active in bacteria and inactive in human hosts. It has broad substrate specificity. Deformylation liberates a free amino group of methionine (or another amino acid or an amino acid analog tolerated as an R3 of the substrate, such as norleucine) which can perform a subsequent nucleophilic attack. With a rationally designed dipeptide or an equivalent peptidomimetic fragment of the substrate the free amino group can attack an optimally positioned phosphorus of the substrate thus forming a cyclic molecule and releasing a toxin. The substrate can be optimized to enhance cyclization. The scheme of the proposed reaction exemplifying a dipeptide-based substrate is given in
FIG. 1 . Here X can be, for example, sulfur (methionine) or —CH2— (norleucine). R1 and R2 are aliphatic radicals that can be selected based on the published SAR data for PDF. Hu et al. (1998). - This invention also provides a composition comprising the prodrug compounds as described above, alone or in combination with other compounds or other agents, known or yet to be discovered, and a carrier. In one aspect, the carrier is another molecule or an inert substance such as a plate or column. In an alternative embodiment, the carrier is a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers are known in the art and described briefly above.
- This invention also provides a composition comprising the prodrug compounds as described above, alone or in combination with other compounds or other agents, known or yet to be discovered, and a carrier. Any of the above noted compounds can be combined with a carrier, such as a pharmaceutically acceptable carrier, and/or an additional effective agent such as an antibiotic. These compounds and compositions are also useful in combination with known or yet to be discovered therapeutics and therapeutic methods to enhance the therapy or efficacy of the drug.
- Also provided by this invention is a method for inhibiting the growth of a PDF expressing microorganism by contacting the microorganism with an effective amount of the compound as described above. Methods to detect PDF expression are known in the art. See, for example, Wei, et al. (1997). This method is particularly useful in inhibiting the growth of gram-positive and gram-negative microorganisms, e.g., S. aureus, S. epidermidis, K. pneumoniae, E. aerogenes, E. cloacae, M. catarrhalis, E. coli, E. faecalis, H. influenzae and P. aeruginosa. and those identified in Table 2, below. This method can be practiced in vitro, ex vivo and in vivo. Further provided is a method for alleviating the symptoms of an infection in a subject, wherein the infection is caused by a PDF expressing microorganism, by administering or delivering to the subject an effective amount of the compound described above. Also provided by this invention is a method for treating an infection caused by a PDF expressing microorganism by administering or delivering to the subject an effective amount of the compound described above. A “subject” is defined above and includes mammals such as human patients. Examples of PDF expressing microorganims and the corresponding diseases and symptoms caused by infection by these microorganisms, are provided in Table 2, below.
TABLE 2 Disease or Symptom Caused by PDF Expressing Microorganism Infection Gram-Positive Staphylococcus aureus major human pathogen, bacteremia, pneumonia Staphylococcus epidermidis and urinary tract infections, other coagulase-negative osteomyelitis, bacteremia staphylococci Streptococcus pyogenes bacteremia, lymphagitis, pneumonia Streptococcus pneumoniae pneumonia, otitis media, sinusitis Streptococcus agalactiae primary bacteremia, pneumonia, endocarditis, osteomyelitis Enterococcus species urinary tract infections, bacteremia, endocarditis, intra- abdominal and pelvic infections, neonatal sepsis Gram-Negative Neisseria gonorrhoeae genital infection, perihepatitis Moraxella catarrhalis otitis media, lower respiratory tract infections, pneumonia, bacteremia Campylobacter jejuni acute enteritis, acute colitis, bacteremia Enterobacteriaceae (including enteric infections, urinary tract Escherichia, Salmonella, Klebsiella, infections, respiratory Enterobacter) infections, bacteremia Pseudomonas aeruginosa endocarditis, respiratory infections, bacteremia, central nervous system infections Acinetobacter species respiratory tract infections, bacteremia, genitourinary Haemophilus influenzae meningitis, epiglottitis, pneumonia, bacteremia - In the clinical use of the prodrug, antibiotics will likely follow well established guidelines. Dosage will likely be similar to those already employed for most other antibiotics. It is estimated that a dose of prodrug will be in the range of 100 μg to 100 mg to 1 gm, or given once every eight hours, or once a day, for one or two weeks, or until the patient tests negative for infectious organisms.
- The compounds of this invention are expected to be administered in doses that reflect the literature doses for the active compounds of which they are prodrugs, with the difference in molecular weight being taken into account. Thus, it is estimated that the dosage for a prodrug hereof will typically be in the range of 100 μg to 100 mg to 1 gm.
- In one aspect, the invention encompasses a method of treating or protecting plants from infections caused by PDF expressing microorganisms by applying an effective amount of the substrate prodrug.
- In order to achieve good dispersion and adhesion of the compounds to treat plants, it may be advantageous to formulate the compounds with components that aid dispersion and adhesion. Suitable formulations will be known to those skilled in the art.
- This invention also provides a method for treating or protecting plants from infection by microorganisms expressing PDF by applying an effective amount of the prodrug compound to the foliage, roots or the soil surrounding the plants or roots. These isolated compounds can be combined with known pesticides or insecticides.
- Compounds within the present invention when used to treat or protect plants from infections caused by PDF expressing microorganisms can be formulated as wettable powders, granules and the like, or can be microencapsulated in a suitable medium and the like. Examples of other formulations include, but are not limited to soluble powders, wettable granules, dry flowables, aqueous flowables, wettable dispersible granules, emulsifiable concentrates and aqueous suspensions. Other suitable formulations will be known to those skilled in the art.
- This invention further provides a method for administering the prodrug compound to fish in an amount effective to either prevent or treat an infection caused by PDF expressing microorganisms. The compound may be administered by incorporating the compound into the food supply for the fish. Alternatively, the compound may be added to the water in which fish live, or are contained within. Finally, the compound may be administered to the fish as a suitable pharmaceutical preparation. Other suitable formulations will be known to those skilled in the art. Further provided is a process for producing the prodrugs of this invention. In general the process requires the following steps:
- With respect to the above diagram, X can be sulfur (methionine) or —CH2— (norleucine). R can be R5 or R6 as defined above. Reaction conditions and full names for the abbreviations can be found in the experimental examples infra.
- This invention provides a method for identifying potential therapeutic agents that inhibit the growth of an organism expressing PDF by contacting a sample containing the PDF expressing microorganism with an effective amount of a candidate prodrug compound. In a separate sample, the same microorganism is contacted with an effective amount of a prodrug of this invention. If the agent has comparable anti-proliferative ability as compared to a prodrug as described herein, the candidate is useful to inhibit the growth of or kill a PDF-expressing microorganism.
- The prodrug is contacted with the sample under conditions that favor the activation of the prodrug by PDF and then the sample is assayed for growth inhibition or microbial death. Alternatively, the sample can be tested for the presence of the byproducts of the reaction of PDF on the substrate. Varying amounts of the substrate are contacted with a microorganism that expresses PDF for an amount of time effective for PDF to release the toxin; from the cell, the bacteria is lysed and the analytes are analyzed using methods known in the art (e.g., High Performance Liquid Chromatography (“HPLC”)) to identify the reaction products.
- Varying concentrations of the potential agent are contacted with the sample to determine the optimal effective concentration of the agent. Thus, in one aspect, this invention relates to the discovery, and use thereof, of agents that are selective substrates for PDF.
- Also provided by this invention are kits containing the prodrugs as described herein and instructions necessary to perform the screen.
- The methods of the invention can be practiced in vitro, ex vivo or in vivo. In vivo practice of the invention in an animal such as a rat or mouse provides a convenient animal model system that can be used prior to clinical testing of the therapeutic agent or prodrug. In this system, a potential prodrug will be successful if microbial load is reduced or the symptoms of the infection are ameliorated compared to an untreated, infected animal. It also can be useful to have a separate negative control group of cells or animals which has not been infected, which provides a basis for comparison.
- When practiced in vivo, the candidate prodrug is administered or delivered to the animal in effective amounts. As used herein, the term “administering” for in vivo and ex vivo purposes means providing the subject with an effective amount of the candidate prodrug effective to reduce microbial load. In these instances, the agent or prodrug may be administered with a pharmaceutically acceptable carrier. The agents, prodrugs and compositions of the present invention can be used in the manufacture of medicaments and for the treatment of humans and other animals by administration in accordance with conventional procedures, such as an active ingredient in pharmaceutical compositions.
- Methods of administering pharmaceutical compositions are known to those of ordinary skill in the art and include, but are not limited to, microinjection, intravenous or parenteral administration. The compositions are intended for topical, oral, or local as well as intravenous, subcutaneous and intramuscular administration. Administration can be effected continuously or intermittently throughout the course of the treatment. Methods of determining the most effective means and dosage of administration are known to those of skill in the art and will vary with the prodrug used for therapy, the purpose of the therapy, the microorganism being treated, the severity of the infection, and the subject being treated. Single or multiple administrations can be carried out with the dose level and pattern being selected by the treating physician. For example, the compositions can be administered to a subject already suffering from an antibiotic resistant bacterial infection. In this situation, an effective “therapeutic amount” of the composition is administered to prevent continued and to at least partially arrest microbial growth and proliferation and ameliorate the symptoms associated with an infection.
- However, the prodrugs can be administered to subjects or individuals susceptible to or at risk of developing an infection. In these embodiments, a “prophylactically effective amount” of the composition is administered to maintain cell viability and function at a level near to the pre-infection level.
- Administration in vivo can be effected in one dose, continuously or intermittently throughout the course of treatment. Methods of determining the most effective means and dosage of administration are known to those of skill in the art and will vary with the composition used for therapy, the purpose of the therapy, the target cell being treated, and the subject being treated. Single or multiple administrations can be carried out with the dose level and pattern being selected by the treating physician. Suitable dosage formulations and methods of administering the agents can be found below.
- The pharmaceutical compositions can be administered orally, intranasally, parenterally or by inhalation therapy, and may take the form of tablets, lozenges, granules, capsules, pills, ampoules, suppositories or aerosol form. They may also take the form of suspensions, solutions and emulsions of the active ingredient in aqueous or nonaqueous diluents, syrups, granulates or powders. In addition to an agent of the present invention, the pharmaceutical compositions can also contain other pharmaceutically active compounds or a plurality of compounds of the invention.
- More particularly, an agent of the present invention also referred to herein as the active ingredient, may be administered for therapy by any suitable route including oral, rectal, nasal, topical (including transdermal, aerosol, buccal and sublingual), vaginal, parenteral (including subcutaneous, intramuscular, intravenous and intradermal) and pulmonary. It will also be appreciated that the route will vary with the condition and age of the recipient, and the disease being treated.
- Ideally, the agent should be. administered to achieve peak concentrations of the active compound at sites of disease. This may be achieved, for example, by the intravenous injection of the agent, optionally in saline, or orally administered, for example, as a tablet, capsule or syrup containing the active ingredient. Desirable blood levels of the agent may be maintained by a continuous infusion to provide a therapeutic amount of the active ingredient within disease tissue. The use of operative combinations is contemplated to provide therapeutic combinations requiring a lower total dosage of each component agent than may be required when each individual therapeutic compound or drug is used alone, thereby reducing adverse effects.
- While it is possible for the agent to be administered alone, it is typical to present it as a pharmaceutical formulation comprising at least one active ingredient, as defined above, together with one or more pharmaceutically acceptable carriers therefor and optionally other therapeutic agents. Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient.
- Formulations include those suitable for oral, rectal, nasal, topical (including transdermal, buccal and sublingual), vaginal, parenteral (including subcutaneous, intramuscular, intravenous and intradermal) and pulmonary administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any methods known in the art of pharmacy. Such methods include the step of bringing into association the active ingredient with the carrier that constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then if necessary shaping the product.
- Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets, each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or suspension in an aqueous or non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The active ingredient may also be presented as a bolus, electuary or paste.
- A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder (e.g., povidone, gelatin, hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (e.g., sodium starch glycolate, cross-linked povidone, cross-linked sodium carboxymethyl cellulose) surface-active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile. Tablets may optionally be provided with an enteric coating, to provide release in parts of the gut other than the stomach.
- Formulations suitable for topical administration in the mouth include lozenges comprising the active ingredient in a flavored basis, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
- Pharmaceutical compositions for topical administration according to the present invention may be formulated as an ointment, cream, suspension, lotion, powder, solution, past, gel, spray, aerosol or oil. Alternatively, a formulation may comprise a patch or a dressing such as a bandage or adhesive plaster impregnated with active ingredients and optionally one or more excipients or diluents.
- If desired, the aqueous phase of the cream base may include, for example, at least about 30% w/w of a polyhydric alcohol, i.e., an alcohol having two or more hydroxyl groups such as propylene glycol, butane-1,3-diol, mannitol, sorbitol, glycerol and polyethylene glycol and mixtures thereof. The topical formulations may desirably include a compound that enhances absorption or penetration of the agent through the skin or other affected areas. Examples of such dermal penetration enhancers include dimethylsulfoxide and related analogues.
- The oily phase of the emulsions of this invention may be constituted from known ingredients in a known manner. While this phase may comprise merely an emulsifier (otherwise known as an emulgent), it desirably comprises a mixture of at lease one emulsifier with a fat or an oil or with both a fat and an oil. A hydrophilic emulsifier can be included together with a lipophilic emulsifier that acts as a stabilizer. In one variation, it includes both an oil and a fat. Together, the emulsifier(s) with or without stabilizer(s) make up the so-called emulsifying wax, and the wax together with the oil and/or fat make up the so-called emulsifying ointment base which forms the oily dispersed phase of the cream formulations.
- Emulgents and emulsion stabilizers suitable for use in the formulation of the present invention include Tween 60, Span 80, cetostearyl alcohol, myristyl alcohol, glyceryl monostearate and sodium lauryl sulfate.
- The choice of suitable oils or fats for the formulation is based on achieving the desired cosmetic properties, since the solubility of the active compound in most oils likely to be used in pharmaceutical emulsion formulations is very low. Thus, the cream can be a non-greasy, non-staining and washable product with suitable consistency to avoid leakage from tubes or other containers. Straight or branched chain, mono- or dibasic alkyl esters such as di-isoadipate, isocetyl stearate, propylene glycol diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a blend of branched chain esters known as Crodamol CAP may be used. These may be used alone or in combination depending on the properties required. Alternatively, high melting point lipids such as white soft paraffin and/or liquid paraffin or other mineral oils can be used.
- Formulations suitable for topical administration to the eye also include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent for the agent.
- Formulations for rectal administration may be presented as a suppository with a suitable base comprising, for example, cocoa butter or a salicylate.
- Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the agent, such carriers as are known in the art to be appropriate.
- Formulations suitable for nasal administration, wherein the carrier is a solid, include a coarse powder having a particle size, for example, in the range of about 20 to about 500 microns which is administered as a dry powder or in an inhaler device by rapid inhalation through the nasal passage from a container of the powder held close up to the nose. Suitable formulations wherein the carrier is a liquid for administration as, for example, nasal spray, nasal drops, or by aerosol administration by nebulizer, include aqueous or oily solutions of the agent.
- Formulations suitable for parenteral administration include aqueous and non-aqueous isotonic sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents, and liposomes or other microparticulate systems which are designed to target the compound to blood components or one or more organs. The formulations may be presented in unit-dose or multi-dose sealed containers, for example, ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
- Unit dosage formulations of interest include those containing a daily dose or unit, daily subdose, as herein above-recited, or an appropriate fraction thereof, of a agent.
- It should be understood that in addition to the ingredients particularly mentioned above, the formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question, for example, those suitable for oral administration may include such further agents as sweeteners, thickeners and flavoring agents. It also is intended that the agents, compositions and methods of this invention be combined with other suitable compositions and therapies.
- These agents of this invention and the above noted compounds and their derivatives may be used for the preparation of medicaments for use in the methods described herein.
- The following examples are intended to illustrate, but not limit the invention.
- The following examples of the synthesis of the claimed compounds are meant to be illustrative of the synthesis of the invention and not limit the synthesis of the invention. The synthetic methods, as for example seen below, used to synthesize the compounds are known to those skilled in the art of organic and medicinal chemistry. Substitutions, modifications or additional steps used in the synthesis of the compounds of the present invention known to those skilled in the art of organic and medicinal chemistry are anticipated. See, e.g., J. March, A
DVANCED ORGANIC CHEMISTRY: REACTIONS, MECHANISMS AND STRUCTURE, 4th edition (John Wiley & Sons, NY (1992)). In addition, it is understood that, for compounds having one or more asymmetric centers, both the racemic mixture and enantiomerically enhanced (i.e., one entantiomer exists in greater than 50% of the mixture) or enantiomerically pure (one enantiomer comprises 90% or more of the mixture) compounds are within the scope of this invention. -
- The synthesis of the 1-(N-benzyloxycarbonyl)-aminopropylphosphonate diphenyl ester has been performed following the method of Oleksyszyn (Synthesis, 1979, pp 985-986). A mixture of triphenyl phosphite (27.1 mL, 100 mmol), propanale (11.25 mL, 150 mmol), benzyl carbamate (15.28 g, 100 mmol) and glacial acetic acid (15 mL) was stirred for 1 hour at room temperature. The mixture was then heated at 85° C. for 1 hour. The volatile products were removed on a rotary evaporator on a boiling water bath obtaining an oily residue that was purified by column chromatography (silica gel; eluent: 40% ethyl acetate in hexane).
- 31P NMR (CDCl3, 500 MHz): 18.15; 1H NMR (CDCl3, 500 MHz): 1.09 (t, 3H), 1.79 (m, 1H), 2.11 (m, 1H), 4.42 (m, 1H), 5.12 (s, 2H), 7.0-7.38 (m, 15H).
-
- Compound 1 (4.0 g, 9.4 mmol) was partially dissolved in 2M aqueous solution of sodium hydroxide (20 mL). The resulting suspension was stirred at room temperature for 18 hours. The reaction mixture was then washed with dichloromethane (2×40 mL) and the aqueous layer was acidified (pH 0) with 2N sulfuric acid (45 mL). The aqueous layer was extracted with dichloromethane (85 mL) and then with ethyl acetate (2×85 mL). The organic phase was dried over sodium sulfate for 30 minutes. After filtration of the drying agent and evaporation of the volatiles,
compound 2 was obtained (2.98 g., 8.5 mmol); 31P NMR (D2O, 500 MHz): 19.21; 1H NMR (D2O, 500 MHz): 0.94 (t, 3H, J=Hz), 1.58 (m, 1H), 1.90 (m, 1H), 3.76 (m, 1H), 5.0 (s, 2H), 7.06 (m, 2H), 7.15 (m, 1H), 7.36 (m, 2H), 7.41 (m, 4H). -
- Compound 2 (1.3 g, 3.72 mmol), was partially dissolved in anhydrous dichloromethane (10 mL). Thionyl chloride (800 ul) was added to the mixture followed by addition of a catalytic amount of anhydrous pyridine (10 ul). The resulting reaction mixture was stirred under argon atmosphere for 30 minutes. The volatiles were removed under vacuo, and the residue was left under high vacuo for 2 hours. The crude phosphonochloridate was then redissolved in anhydrous dichloromethane (5 mL) and the mixture was added dropwise, at 0° C., to a stirring solution of triclosan (1.07 g., 1 eq.) and anhydrous triethyalmine (520 ul, 1 eq.) in anhydrous dichloromethane (5 mL). The reaction mixture was allowed to warm up to room temperature and was stirred under argon atmosphere for 1 hour. The reaction mixture was then extracted with water (10 mL). The organic phase was dried over sodium sulfate for 30 minutes. After filtration of the drying agent and evaporation of the volatiles by vacuum distillation, the residue was purified by column chromatography (silica gel; eluent: 20% ethyl acetate in hexane) obtaining compound 3 (550 mg); 31P NMR (CDCl3, 500 MHz): 19.08, 19.29; 1H NMR (CDCl3, 500 MHz): 1.03 (m, 3H), 1.67 (m, 1H), 2.05 (m, 1H), 4.41 (m, 1H), 5.08 (m, 2H), 6.73 (m, 1H), 6.83 (m, 2H), 7.13 (m, 5H), 7.30 (m, 8H).
-
- Compound 3 (200 mg, 0.322 mmol) was dissolved in absolute ethanol (80 mL) and then added with Pd 10% on carbon (80 mg) and trifluoroacetic acid (40 ul). The mixture was then shaken under hydrogen atmosphere (10 psi) for 30 minutes. After filtration through a pad of celite, the solution was concentrated to dryness, and the resulting dense oil was left under high vacuo for 2 hours. The oil was then dissolved in anhydrous tetrahydrofurane (5 mL), and the resulting solution was added to a stirring solution of N-formyl methionine (60 mg) and 1,3-dicyclohexyl carbodiimide (66 mg) in anhydrous tetrahydrofurane (3 mL). Anhydrous triethylamine (50 ul,) was then added to the mixture, and the reaction was allowed to stir for 12 hours under argon atmosphere at room temperature. After the filtration of the precipitated material, the mixture was extracted with water (10 mL). The organic phase was dried over sodium sulfate for 30 minutes. After filtration of the drying agent and evaporation of the volatiles by vacuum distillation, the residue was purified by preparative HPLC (reverse phase, C18; gradient from 50% acetonitrile in water to 100% acetonitrile over 40 minutes). The desired compound was isolated as a mixture of diastereoisomers with retention time of 12.28 minutes. 31P NMR (CDCl3, 500 MHz): 18.04, 18.16, 18.32; 1H NMR (CDCl3, 500 MHz) selected signals: 1.25 (m, 5H), 1.07-2.09 (m, 7H), 4.65 (m, 1H), 6.7-7.47 (m, 11H), 8.12 (s, 1H); m/e 645.
- It is to be understood that while the invention has been described in conjunction with the above embodiments, that the foregoing description and examples are intended to illustrate and not limit the scope of the invention. Other aspects, advantages and modifications within the scope of the invention will be apparent to those skilled in the art to which the invention pertains.
- Apfel, C. et al. (2000) J. Med. Chem. 43:2324-2331.
- Apfel et al. (2001a) Anti. Agents and Chemo. 45(4):1053-1057.
- Apfel et al. (2001b) Anti. Agents and Chemo. 45(4):1058-1064.
- Becker, A. et al. (1998) Nat. Struct. Biol. 5(12): 1053-8.
- Chan, M. K. et al. (1997) Biochemistry 36(45):13904-9.
- Chen, D. Z. et al. (2000) Biochemistry 39(6):1256-62.
- Clements, J. M. et al. (2001) Anti. Agents and Chemo. 45(2):563-570.
- de Groot, F. M. H. et al. (2000) J. Med. Chem. 43:3093-3102.
- Durand et al. (1999) Arch. Bio. And Biophysics. 367(2): 297-302.
- Giglione, C. et al. (2000a) Mol. Microbiol. 36:1197205.
- Giglione, C. et al. (2000b) EMBO J. 19(21):5916-5929.
- Guilloteau J-P. et al. (2002) J. Mol. Biol. 320(5):951-962
- Hao, B. et al. (1999) Biochemistry 38(15):4712-9.
- Hu, Y. J. et al. (1998) Bioorg Med Chem Lett. 8(18):2479-82.
- Huntington, K. M. et al. (2000) Biochemistry 39(15):4543-51.
- Jayasekera, M. M. et al. (2000) Arch. Biochm. Biophys. 381(2):313-316.
- Meinnel, T. (1999) Pathol. Biol. 47:780-783.
- Meinnel, T. et al. (1993) Biochimie. 75(12):1061-75. Review.
- Nelson, D. L. et al. (2000) Principles of Biochemistry. 2000, ed. Lehninger,
- Ragusa S., et al. (2000) J. Mol. Biol., 280, 551-523.
- Rajagopalan, P. T. et al. (1997) Biochemistry 36(45):13910-8.
- Rajagopalan, P. T. et al. (1998) Biol Chem. 273(35):22305-10.
- Wei Y. et al. (1997) Anal Biochem. 250(1):29-34.
- Wei, Y. et al. (2000) J Comb Chem. 2(6):650-7.
- Wei, Y. et al. (2000b) Bioorg Med Chem Lett. 10(10):1073-6.
- Wise, R. et al (2002) Anti. Agents and Chemo, 46(4): 1117-1118
- Yuan, Z. et al. (2001) Drug Discovery Today, 6(18): 954-961
Claims (30)
1. A compound having the structure:
wherein:
R1 is hydrogen or CH3;
R4 is selected from the group consisting of a substituted or unsubstituted aryl group, a substituted or unsubstituted, saturated or unsaturated C1-C6 alkyl group and
—CH2CH2XCH3, wherein X is selected from the group consisting of oxygen, sulfur and CH2;
R5 and R6 are independently selected from the group consisting of hydrogen, a substituted or unsubstituted C5-C14 aryl group and a substituted or unsubstituted, saturated or unsaturated C1-C6 alkyl group;
=A1 is either absent, in which case the carbon to which it was attached becomes a CH2 group, or A1 is selected from the group consisting of oxygen, sulfur, NH, NOH, NR8, and CR9R10, wherein R8, R9 and R10 are independently selected from the group consisting of hydrogen and C1-C6 alkyl;
=A2 is either absent, in which case the carbon to which it was attached becomes a CH2 group, or A2 is selected from the group consisting of oxygen, sulfur, NH, NOH and NR11 wherein R11 is selected from the group consisting of hydrogen and C1-C6alkyl;
B1 is either absent or is selected from the group consisting of oxygen, sulfur, NR12 and
CR13R14, wherein R12R13 and R14 are independently selected from the group consisting of hydrogen and a substituted or unsubstituted saturated or unsaturated alkyl;
B2 is selected from the group consisting of carbon, oxygen and nitrogen, wherein, when B2 is oxygen, R5 and R6 are absent and when B2 is nitrogen, one of R5 or R6 is absent;
B1 may be joined through R12, R13 or R14 to R5 or R6 to form a saturated or unsaturated, substituted or unsubstituted ring which may contain 0-3 nitrogen atoms and/or 0-1 oxygen or sulfur atoms;
B3 and B4 are independently absent or selected from the group consisting of oxygen, sulfur, NH, CH2, NR17, CHR18, CR21R22 and, when either linker1-B5-Toxin1 or linker2-B6-Toxin2 is absent, OR15, SR16, NR19R20 and CR23R24R25, wherein R15—R25 are independently selected from the group consisting of hydrogen, substituted or unsubstituted, saturated or unsaturated alkyl and substituted or unsubstituted aryl;
B3 or B4 may be joined through one of R15—R25 to B1, R5 or R6 to form a saturated or unsaturated, substituted or unsubstituted ring which contains one phosphorus atom and which may contain 0-3 nitrogen atoms and/or 0-1 oxygen or sulfur atoms;
B5 and B6 are independently absent or selected from the group consisting of oxygen, sulfur, OC(═O), SC(═S), OC(═O)NH, SC(═S)NH, OC(═S)NH, N(R26) and C(R27)(R28), wherein R26, R27 and R28 are independently selected from the group consisting of hydrogen and a substituted or unsubstituted, saturated or unsaturated alkyl;
Linker1 and Linker2 are independently absent or present and if present are traceless; and, one of Toxin1 or Toxin2 may be absent.
2. The compound of claim 1 , wherein:
R1 is hydrogen; and,
R4 is CH2CH2XCH3, wherein X is selected from the group consisting of CH2, sulfur and oxygen.
3. The compound of claim 2 , wherein X is sulfur.
4. The compound of claim 3 , wherein A1 and A2 are both oxygen.
5. The compound of claim 4 , wherein Linker1-B5-Toxin1 is absent.
6. The compound of claim 5 , wherein B1 is absent.
7. The compound of claim 5 , wherein B2 is carbon.
8. The compound of claim 5 , wherein B2 is nitrogen.
9. The compound of claim 5 , wherein B3 is selected from the group consisting of OH, OCH3, OCH2CH3 and OC6H5.
10. The compound of claim 5 , wherein Linker2 is selected from the group consisting of
substituted or unsubstituted allyl;
substituted or unsubstituted benzyl,
C6H4CH2X1C(═X2), wherein X1 and X2 are independently selected from the group consisting of oxygen, sulfur and N(R29), wherein R29 is hydrogen or C1-C6 alkyl; and,
(CH2)nN(R)C(═O), wherein n is 2 or 3 and R is hydrogen or C1-C6 alkyl.
11. The compound of claim 10 , wherein B6 is absent.
12. The compound of claim 1 , wherein Toxin1 and Toxin2 are independently selected from the group consisting of aminoglycosides, mitomycin, CC-1065, ducarmycin, cyclopropyl indole, cyclopropyl benzoindole analogs, anthracyclins, vinca alkaloids, mitomycins, bleomycins, penicillins, cephalosporins, oxacillins, carbopenems, tetracyclins, chloramphenicols, macrolides, cycloserines, fluoroquinolones (including, but not limited to, ciprofloxacin and norfloxacin), glycopeptides, aminoglycosides, peptide antibiotics, oxazolidinones, quinolones, sulfonamides, cytotoxic nucleosides, pteridine family, nitrogen mustards, polyhalogenated biaryl ethers, diynenes, podophillotoxins, taxoids, doxorubicin, carminomycin, daunorubicin, aminopterin, methotrexate, methopterin, dichloromethotrexate, mitomycin C, porfiromycin, 6-mercaptopurine, cytosine arabinoside, podophillotoxin, etoposide, etoposide phosphate, melphalan, vindesine, vinblastine, vincristine, leurosidine, leurosine, bis-(2-chloroethyl)amine, trichlorcarban, trichlorocarbanilide, triclosan, tribromosalicylanilide, sulphamethoxazole, chloramphenicol, cycloserine, trimethoprim, chlorhexidine, hexachlorophene, fentichlor, 5-chloro-2-(2,4-dichlorophenoxy)phenol, 4-chloro-2-(2,4-dichlorophenoxy)phenol, 3-chloro-2-(2,4-dichlorophenoxy)phenol, 6-chloro-2-(2,4-dichlorophenoxy)phenol, 5-chloro-2-(3,4-dichlorophenoxy)phenol, 5-chloro-2-(2,5-dichlorophenoxy)phenol, 5-chloro-2-(3,5-dichlorophenoxy)phenol, 2,2′-dihydroxy biphenyl ether, halogenated 2-hydroxybenzophenones, 2-mercaptopyridine-N-oxide, combretastatin, camptothesin, apoptolidene, cisplatin, epothilone, halichondrin, hemiasterlin, methioprim, thapsigargin, chloroquine, 4-hydroxycyclophosphamide, etoposide, colchicine, melphalan, quercetin, genistein, erbstatin, N-(4-aminobutyl)-5-chloro-2-naphtalen-sulfonamide, pyridinyloxazol-2-one, isoquinolyloxazolone-2-one, verapamil, quinine, quinidine, and chloroquine.
13. The compound of claim 11 , wherein Toxin2 is selected from the group consisting of aminoglycosides, mitomycin, CC-1065, ducarmycin, cyclopropyl indole, cyclopropyl benzoindole analogs, anthracyclins, vinca alkaloids, mitomycins, bleomycins, penicillins, cephalosporins, oxacillins, carbopenems, tetracyclins, chloramphenicols, macrolides, cycloserines, fluoroquinolones (including, but not limited to, ciprofloxacin and norfloxacin), glycopeptides, aminoglycosides, peptide antibiotics, oxazolidinones, quinolones, sulfonamides, cytotoxic nucleosides, pteridine family, nitrogen mustards, polyhalogenated biaryl ethers, diynenes, podophillotoxins, taxoids, doxorubicin, carminomycin, daunorubicin, aminopterin, methotrexate, methopterin, dichloromethotrexate, mitomycin C, porfiromycin, 6-mercaptopurine, cytosine arabinoside, podophillotoxin, etoposide, etoposide phosphate, melphalan, vindesine, vinblastine, vincristine, leurosidine, leurosine, bis-(2-chloroethyl)amine, trichlorcarban, trichlorocarbanilide, triclosan, tribromosalicylanilide, sulphamethoxazole, chloramphenicol, cycloserine, trimethoprim, chlorhexidine, hexachlorophene, fentichlor, 5-chloro-2-(2,4-dichlorophenoxy)phenol, 4-chloro-2-(2,4-dichlorophenoxy)phenol, 3-chloro-2-(2,4-dichlorophenoxy)phenol, 6-chloro-2-(2,4-dichlorophenoxy)phenol, 5-chloro-2-(3,4-dichlorophenoxy)phenol, 5-chloro-2-(2,5-dichlorophenoxy)phenol, 5-chloro-2-(3,5-dichlorophenoxy)phenol, 2,2′-dihydroxy biphenyl ether, halogenated 2-hydroxybenzophenones, 2-mercaptopyridine-N-oxide, combretastatin, camptothesin, apoptolidene, cisplatin, epothilone, halichondrin, hemiasterlin, methioprim, thapsigargin, chloroquine, 4-hydroxycyclophosphamide, etoposide, colchicine, melphalan, quercetin, genistein, erbstatin, N-(4-aminobutyl)-5-chloro-2-naphtalen-sulfonamide, pyridinyloxazol-2-one, isoquinolyloxazolone-2-one, verapamil, quinine, quinidine, and chloroquine.
14. The compound of claim 13 , wherein Toxin2 is a quinolone.
15. The compound of claim 13 , wherein Toxin2 is selected from the group consisting of triclosan, cyclopropylindole, cyclopropylbenzoindole and derivatives thereof.
16. The compound of claim 5 , wherein B1 is joined to R5 or R6 to form a ring.
17. (canceled)
18. (canceled)
19. A method for the treatment of a disease caused by a microorganism expressing a peptide deformylase enzyme (PDF), comprising administering to a patient in need thereof an effective amount of a compound of claim 1 .
20. A method for inhibiting the growth of a microorganism that expresses a peptide deformylase enzyme (PDF), comprising contacting the microorganism with an effective amount of a compound of claim 1 .
21. A method for alleviating the symptoms of an infection in a subject in need thereof wherein the symptoms are caused by a microorganism that expresses a peptide deformylase enzyme (PDF), comprising administering to the subject an effective amount of a compound of claim 1 .
22. The method of any of claims 19 to 21 , wherein the microorganism expressing PDF is selected from the group consisting of S. aureus, S. epidermidis, K. pneumoniae, E. aerogenes, E. cloacae, M. catarrhalis, E. coli, E. faecalis, H. influenzae and P. aeruginosa.
23. The method of claim 19 , wherein the disease is selected from the group consisting of acute colitis, acute enteritis, bacteremia, endocarditis, epiglottitis, lymphagitis, pneumonia, meningitis, neonatal sepsis, osteomyelitis, otitis media, perihepatitis and sinusitis.
24. The method of claim 21 , wherein the infection is selected from the group consisting of central nervous system infections, enteric infections, genital infections, lower respiratory tract infections, neonatal sepsis and urinary tract infection.
25. The method of claim 20 , wherein the contacting is in vitro or ex vivo.
26. The method of any of claims 19 to 21 , further comprising administering an effective amount of an antibiotic.
27. The method of any of claim 26 , wherein the compound is administered with a pharmaceutically acceptable carrier.
28. The method of claim 21 , wherein the subject is selected from a fish or an animal.
29. The method of claim 28 , wherein the subject is a fish.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/256,061 US20060063743A1 (en) | 2002-11-14 | 2005-10-21 | Peptide deformylase activated prodrugs |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42677102P | 2002-11-14 | 2002-11-14 | |
US10/714,255 US7001922B2 (en) | 2002-11-14 | 2003-11-14 | Peptide deformylase activated prodrugs |
US11/256,061 US20060063743A1 (en) | 2002-11-14 | 2005-10-21 | Peptide deformylase activated prodrugs |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/714,255 Division US7001922B2 (en) | 2002-11-14 | 2003-11-14 | Peptide deformylase activated prodrugs |
Publications (1)
Publication Number | Publication Date |
---|---|
US20060063743A1 true US20060063743A1 (en) | 2006-03-23 |
Family
ID=32313139
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/714,255 Expired - Fee Related US7001922B2 (en) | 2002-11-14 | 2003-11-14 | Peptide deformylase activated prodrugs |
US11/256,061 Abandoned US20060063743A1 (en) | 2002-11-14 | 2005-10-21 | Peptide deformylase activated prodrugs |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/714,255 Expired - Fee Related US7001922B2 (en) | 2002-11-14 | 2003-11-14 | Peptide deformylase activated prodrugs |
Country Status (8)
Country | Link |
---|---|
US (2) | US7001922B2 (en) |
EP (1) | EP1585751A4 (en) |
JP (1) | JP2006514009A (en) |
AU (1) | AU2003290779A1 (en) |
BR (1) | BR0315537A (en) |
CA (1) | CA2505914A1 (en) |
TW (1) | TW200418508A (en) |
WO (1) | WO2004043400A2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1399467A4 (en) | 2001-05-09 | 2004-09-15 | Newbiotics Inc | Peptide deformylase activated prodrugs |
DK1506203T3 (en) | 2002-08-23 | 2007-05-14 | Sloan Kettering Inst Cancer | Synthesis of epothilones, intermediates thereof, analogs thereof and uses thereof |
US7649006B2 (en) | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
EP1845087A1 (en) * | 2006-04-14 | 2007-10-17 | Mutabilis SA | Hydroxyphenyl derivatives and biological applications thereof |
EP2473480B1 (en) | 2009-09-01 | 2016-06-01 | FAB Pharma SAS | Novel antibacterial hydroxyphenyl compound |
DK3176165T3 (en) * | 2014-07-30 | 2019-01-02 | Teijin Pharma Ltd | CRYSTAL OF AZOLBENZENE DERIVATIVE AS XANTHINOXIDASE INHIBITOR |
Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4053638A (en) * | 1970-05-06 | 1977-10-11 | William Wrigley Jr. Company | Anticaries confectioneries and oral health products |
US4071511A (en) * | 1975-08-14 | 1978-01-31 | Ajinomoto Co., Inc. | Method of removing formyl groups from N-formyl-amino acid and N-formyl-peptide esters having free carboxyl groups |
US4083974A (en) * | 1977-03-07 | 1978-04-11 | The Upjohn Company | Topical steroidal anti-inflammatory preparations containing polyoxypropylene 15 stearyl ether |
US4415590A (en) * | 1982-04-26 | 1983-11-15 | Betamed Pharmaceuticals, Inc. | Herpes treatment |
US4427660A (en) * | 1982-03-03 | 1984-01-24 | Research Corporation | Formyl-methionyl chemotatic peptide antibiotic conjugates useful in treating infections |
US5274113A (en) * | 1991-11-01 | 1993-12-28 | Molecular Probes, Inc. | Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates |
US5350681A (en) * | 1986-08-18 | 1994-09-27 | The Coca-Cola Company | Enzymatic membrane method for the synthesis and separation of peptides |
US5918568A (en) * | 1996-08-26 | 1999-07-06 | Pharmalett Denmark A/S | Method of medicating and individualizing treatment shampoo for dermatological disturbances of companion animals |
US6110908A (en) * | 1995-03-31 | 2000-08-29 | Guthery; B. Eugene | Fast acting and persistent topical antiseptic |
US6143790A (en) * | 1994-03-10 | 2000-11-07 | G.D. Searle & Co. | L-N6 -(1-iminoethyl)lysine derivatives useful as nitric oxide synthase inhibitors |
US6159706A (en) * | 1997-12-23 | 2000-12-12 | Newbiotics, Inc. | Application of enzyme prodrugs as anti-infective agents |
US6245750B1 (en) * | 1998-01-23 | 2001-06-12 | Newbiotics, Inc. | Enzyme catalyzed therapeutic agents |
US6448058B1 (en) * | 1997-09-12 | 2002-09-10 | Versicor, Inc. | Methods for solid phase synthesis of mercapto compounds and derivatives, combinatorial libraries thereof and compositions obtained thereby |
US6613879B1 (en) * | 1999-05-14 | 2003-09-02 | Boehringer Ingelheim Pharma Kg | FAP-activated anti-tumour compounds |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1081511B (en) * | 1976-07-13 | 1985-05-21 | Hoffmann La Roche | PEPTIDE DERIVATIVES AND THEIR PREPARATION |
HU181013B (en) | 1980-01-25 | 1983-05-30 | Gyogyszerkutato Intezet | Process for preparing new enkephalin analogues |
CA2264227A1 (en) | 1996-09-27 | 1998-04-02 | Raymond A. Firestone | Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells |
WO1999008110A1 (en) | 1997-08-08 | 1999-02-18 | Newbiotics, Inc. | Methods and compositions for overcoming resistance to biologic and chemotherapy |
EP1200455B1 (en) | 1999-07-22 | 2009-04-22 | Celmed Oncology (USA), Inc. | Enzyme catalyzed therapeutic activation |
EP1399467A4 (en) | 2001-05-09 | 2004-09-15 | Newbiotics Inc | Peptide deformylase activated prodrugs |
US20050096254A1 (en) | 2002-04-18 | 2005-05-05 | Sergeeva Maria V. | Peptide deformylase activated prodrugs |
-
2003
- 2003-11-14 US US10/714,255 patent/US7001922B2/en not_active Expired - Fee Related
- 2003-11-14 AU AU2003290779A patent/AU2003290779A1/en not_active Abandoned
- 2003-11-14 CA CA002505914A patent/CA2505914A1/en not_active Abandoned
- 2003-11-14 BR BR0315537-4A patent/BR0315537A/en not_active Application Discontinuation
- 2003-11-14 WO PCT/US2003/036124 patent/WO2004043400A2/en active Application Filing
- 2003-11-14 JP JP2004552156A patent/JP2006514009A/en not_active Withdrawn
- 2003-11-14 TW TW092132018A patent/TW200418508A/en unknown
- 2003-11-14 EP EP03783362A patent/EP1585751A4/en not_active Withdrawn
-
2005
- 2005-10-21 US US11/256,061 patent/US20060063743A1/en not_active Abandoned
Patent Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4053638A (en) * | 1970-05-06 | 1977-10-11 | William Wrigley Jr. Company | Anticaries confectioneries and oral health products |
US4071511A (en) * | 1975-08-14 | 1978-01-31 | Ajinomoto Co., Inc. | Method of removing formyl groups from N-formyl-amino acid and N-formyl-peptide esters having free carboxyl groups |
US4083974A (en) * | 1977-03-07 | 1978-04-11 | The Upjohn Company | Topical steroidal anti-inflammatory preparations containing polyoxypropylene 15 stearyl ether |
US4427660A (en) * | 1982-03-03 | 1984-01-24 | Research Corporation | Formyl-methionyl chemotatic peptide antibiotic conjugates useful in treating infections |
US4415590A (en) * | 1982-04-26 | 1983-11-15 | Betamed Pharmaceuticals, Inc. | Herpes treatment |
US5350681A (en) * | 1986-08-18 | 1994-09-27 | The Coca-Cola Company | Enzymatic membrane method for the synthesis and separation of peptides |
US5274113A (en) * | 1991-11-01 | 1993-12-28 | Molecular Probes, Inc. | Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates |
US6143790A (en) * | 1994-03-10 | 2000-11-07 | G.D. Searle & Co. | L-N6 -(1-iminoethyl)lysine derivatives useful as nitric oxide synthase inhibitors |
US6110908A (en) * | 1995-03-31 | 2000-08-29 | Guthery; B. Eugene | Fast acting and persistent topical antiseptic |
US5918568A (en) * | 1996-08-26 | 1999-07-06 | Pharmalett Denmark A/S | Method of medicating and individualizing treatment shampoo for dermatological disturbances of companion animals |
US6448058B1 (en) * | 1997-09-12 | 2002-09-10 | Versicor, Inc. | Methods for solid phase synthesis of mercapto compounds and derivatives, combinatorial libraries thereof and compositions obtained thereby |
US6159706A (en) * | 1997-12-23 | 2000-12-12 | Newbiotics, Inc. | Application of enzyme prodrugs as anti-infective agents |
US6245750B1 (en) * | 1998-01-23 | 2001-06-12 | Newbiotics, Inc. | Enzyme catalyzed therapeutic agents |
US6339151B1 (en) * | 1998-01-23 | 2002-01-15 | Newbiotics, Inc. | Enzyme catalyzed therapeutic agents |
US6613879B1 (en) * | 1999-05-14 | 2003-09-02 | Boehringer Ingelheim Pharma Kg | FAP-activated anti-tumour compounds |
Also Published As
Publication number | Publication date |
---|---|
US7001922B2 (en) | 2006-02-21 |
TW200418508A (en) | 2004-10-01 |
WO2004043400A3 (en) | 2004-09-30 |
WO2004043400A2 (en) | 2004-05-27 |
US20040236096A1 (en) | 2004-11-25 |
CA2505914A1 (en) | 2004-05-27 |
BR0315537A (en) | 2005-09-27 |
AU2003290779A1 (en) | 2004-06-03 |
EP1585751A2 (en) | 2005-10-19 |
EP1585751A4 (en) | 2008-08-13 |
JP2006514009A (en) | 2006-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200140460A1 (en) | Antibacterial therapeutics and prophylactics | |
JP2005508311A (en) | N-monoacylated derivatives of o-phenylenediamine, their 6-membered heterocyclic analogs, and their use as drugs | |
US20060063743A1 (en) | Peptide deformylase activated prodrugs | |
US10662164B2 (en) | Non-beta lactam antibiotics | |
US20120322768A1 (en) | Compounds, compositions and methods for treating protozoan infections | |
US20020115642A1 (en) | Beta-lactam antibiotics | |
US7163923B2 (en) | Peptide deformylase activated prodrugs | |
US7109190B2 (en) | Carbacephem β-lactam antibiotics | |
AU2002314773A1 (en) | Peptide deformylase activated prodrugs | |
US20050096254A1 (en) | Peptide deformylase activated prodrugs | |
US10350177B2 (en) | Antibacterial S-heterosubstituted disulfides | |
KR20210087448A (en) | Indane derivatives used in the prevention or treatment of bacterial infections | |
US10717757B2 (en) | Ketolides having antibacterial activity | |
US11795192B2 (en) | Antimicrobial compounds, compositions, and uses thereof | |
US20220348605A1 (en) | Antimicrobial compounds, compositions, and uses thereof | |
KR20050018809A (en) | Peptide deformylase activated prodrugs | |
AU2001241878A1 (en) | Anti-infective ECTA |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |